daunorubicin has been researched along with etoposide in 486 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (9.05) | 18.7374 |
| 1990's | 187 (38.48) | 18.2507 |
| 2000's | 159 (32.72) | 29.6817 |
| 2010's | 86 (17.70) | 24.3611 |
| 2020's | 10 (2.06) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Barrows, LR; Ireland, CM; Kokoshka, JM | 1 |
| Heijn, M; Hooijberg, JH; Lankelma, J; Scheffer, GL; Szabó, G; Westerhoff, HV | 1 |
| Cole, SP; Deeley, RG; Grant, CE; Hipfner, DR; Loe, DW; Stride, BD | 1 |
| Aubé, J; Borchardt, RT; Gao, J; Murase, O; Schowen, RL | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Borchardt, RT; Horie, K; Tang, F | 2 |
| Belinsky, MG; Chen, ZS; Kruh, GD; Shchaveleva, I; Zeng, H | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Rodemann, T; Zhuang, L | 1 |
| Dantzig, AH; Godinot, N; Iversen, PW; Perry, WL; Tabas, L; Williams, DC; Xia, X | 1 |
| Cole, SP; Deeley, RG; Grant, CE; Nunoya, K; Zhang, D | 1 |
| Baruchello, R; Bonora, C; Buscemi, F; Grimaudo, S; Pizzirani, D; Roberti, M; Rondanin, R; Simoni, D; Tolomeo, M | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barbusca, E; Cannizzo, G; Cascioferro, S; Daidone, G; Maggio, B; Mancuso, S; Plescia, F; Raffa, D; Raimondi, MV; Tolomeo, M | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Ahn, G; Bailly, C; Baldeyrou, B; Couture, A; Goossens, JF; Grandclaudon, P; Lansiaux, A; Ryckebusch, A; Schifano-Faux, N | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Ahn, G; Baldeyrou, B; Couture, A; Goossens, JF; Grandclaudon, P; Lansiaux, A; Ryckebusch, A; Schifano-Faux, N | 1 |
| Cancemi, G; Cascioferro, S; Daidone, G; Grimaudo, S; Maggio, B; Plescia, F; Raffa, D; Raimondi, MV; Tolomeo, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amiel, JL; Hayat, M; Mathé, G; Pouillart, P; Schwarzenberg, L; Tubiana, M | 1 |
| Wiernik, PH | 2 |
| Bernier, RD; Mease, AD; Mosijczuk, AD; Ruymann, FB | 1 |
| Dombernowsky, P; Nissen, NI | 1 |
| Alberto, P; Cavalli, F; Sauter, C; Senn, HJ | 1 |
| Broxterman, HJ; de Vries, EG; Feller, N; Kuiper, CM; Lankelma, J; Pinedo, HM; Versantvoort, CH | 1 |
| Mitchell, DC; Win, N | 1 |
| Sumner, AT | 1 |
| Glisson, BS; Killary, AM; Merta, P; Ross, WE; Siciliano, J; Siciliano, MJ | 1 |
| Gottesman, MM; Mickisch, GH; Pai, LH; Pastan, I | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Asano, S; Ikebuchi, K; Irie, S; Ogura, H; Okamoto, S; Ozawa, K; Satoh, N; Tani, K; Tojo, A | 1 |
| Chiba, S; Hanazono, Y; Hirai, H; Miura, Y; Miyagawa, K; Miyazono, K; Piao, YF; Sakamoto, S; Taketazu, F; Yazaki, Y | 1 |
| Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J | 1 |
| Gau, JP; Hu, HT; Hwang, WL; Tsai, YT; Young, JH | 1 |
| Brinch, L; Evensen, SA; Stavem, P; Tjønnfjord, G | 1 |
| Belin, T; Champlin, R; Gajewski, J; Lee, M; Nimer, S; Schiller, G; Territo, M | 1 |
| Kimura, F; Mizukami, H; Motoyoshi, K; Nagata, N; Ohtsuki, T; Takagi, S; Takemura, Y; Yamamoto, K | 1 |
| Grever, MR; Gumbart, CH; Head, D; Hynes, HE; Kopecky, KJ; Lipschitz, DA; Ryan, DH; Shiaer, SM; Veith, RW; Vial, RH | 1 |
| Elliott, S; Marlton, P; Meagher, D; Rodwell, R; Taylor, D; Taylor, K; Timms, P; White, S; Wiley, J; Wright, S | 1 |
| Gray, R; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Amadori, S; Avvisati, G; Cacciola, E; Cantore, N; De Laurenzi, A; De Rosa, C; Fioritoni, G; Mandelli, F; Spadea, A; Vegna, ML | 1 |
| Demant, EJ; Friche, E; Jensen, PB; Sehested, M | 1 |
| Greer, JP; Lukens, JN; Whitlock, JA | 1 |
| Beck, WT; Danks, MK | 1 |
| Buckley, JD; Hammond, GD; Lampkin, BC; Woods, WG | 1 |
| Gray, RG; Rees, JK | 1 |
| Andoh, T; Ito, Y; Kawashima, K; Morishima, Y; Morishita, Y; Saito, H; Tanimoto, M; Towatari, M | 1 |
| Kaufmann, SH | 1 |
| Challis, J; Farag, S; Garson, OM; White, J | 1 |
| Diedrich, H; Freund, M; Ganser, A; Gramatzki, M; Haas, R; Heil, G; Henke, M; Heyll, A; Hiddemann, W; Kuse, R | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, B; Harousseau, JL; Ifrah, N; Leprise, PY; Milpied, N | 2 |
| Carbone, TV; Kelleher, JF | 1 |
| Ito, T; Ito, Y; Kitaori, K; Nagai, T; Ohno, R; Okumura, M; Sugiura, I; Takeo, T; Yano, K; Yokomaku, S | 1 |
| Bender-Götze, C; Dopfer, R; Ebell, W; Ehninger, G; Friedrich, W; Gadner, H; Henze, G; Klingebiel, T; Peters, C; Riehm, H | 1 |
| Bastida Vila, P; Giralt López, J; Javier Manchón, G; Olivé Oliveras, T; Ortega Aramburu, JJ; Sánchez, C | 1 |
| Costello, C; McCarthy, D; Mir, N; Nadir, F; Rule, S; Samson, D; Taylor, J | 1 |
| Chrétien, P; Huot, J; Lambert, H; Landry, J; Roy, G | 1 |
| Dölken, G; Fauser, AA; Herbst, EW; Kreisel, W | 1 |
| Granada, I; Las Heras, G; Millá, F; Ribera, JM | 1 |
| Close, P; Meister, L; Ruchelli, E | 1 |
| Larsson, R; Nygren, P | 1 |
| Daniel, JC; Levy, SB; Slapak, CA | 1 |
| Farhi, DC; Rosenthal, NS | 1 |
| Bandini, G; Barbui, T; Bassan, R; Battista, R; Ciolli, S; D'Emilio, E; Leoni, F; Rosti, G; Todeschini, G; Zuffa, E | 1 |
| Mansberg, R; Rowlings, PA; Rozenberg, MC; Yip, MY | 1 |
| Boesen, AM; Brincker, H; Christensen, BE; Drivsholm, A; Ellegaard, J; Hansen, OP; Hippe, E; Jans, H; Jensen, KB; Pedersen-Bjergaard, J | 1 |
| Creutzig, U; Ritter, I; Schellong, G | 1 |
| Alejo, M; Aventin, A; Badell, I; de Moragas, JM; Lopez, D; Pujol, RM; Soler, J | 1 |
| Ciolli, S; Leoni, F; Morfini, M; Patriarchi, S; Rossi Ferrini, P | 1 |
| Creutzig, U; Ritter, J; Schellong, G | 3 |
| Broccia, G; Caronia, F; Di Raimondo, F; Fioritoni, G; Ladogana, S; Leone, G; Liso, V; Musso, M; Neri, A; Petti, MC | 1 |
| Ehninger, G; Fackler-Schwalbe, E; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Löffler, B; Lösch, A; Mitrou, PS | 1 |
| De Boben, M; Diedrich, H; Freund, M; Ganser, A; Heil, G; Henke, M; Heyll, A; Hiddemann, W; Knauf, U; Koch, P | 1 |
| Benjamin, DR; Bernstein, ID; Buckley, JD; Feig, SA; Kim, TH; Lampkin, BC; Ruymann, FB; Smithson, WA; Srivastava, AK; Woods, WG | 1 |
| Chan, TK; Chiu, E; Liang, R; Todd, D | 1 |
| Borgert, CJ; Kroll, DJ; Rowe, TC; Wiedmann, TW | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, C; Harousseau, JL; Ifrah, N; Le Prise, PY; Milpied, N | 1 |
| Kühn, B; Löffler, H; Polchau, H; Rister, M; Suttorp, M | 1 |
| Bauters, F; Estienne, MH; Facon, T; Fenaux, P; Millot, F; Pagniez, D; Preud'homme, C; Vanhaesbroucke, C | 1 |
| Bishop, JF; Cobcroft, R; Dodds, A; Joshua, D; Kronenberg, H; Lowenthal, RM; Ma, D; Matthews, JP; Todd, D; Whiteside, MG | 1 |
| Lampkin, BC | 1 |
| Dahl, GV; Jackson, CW; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
| Cole, SP; Gerlach, JH; Mirski, SE | 1 |
| Catovsky, D; Chessells, JM; Galton, DA; Goldman, JM; Hann, IM; Hoffbrand, AV; Marcus, RE; Newland, AC; Prentice, HG; Stevens, RF | 1 |
| Gray, R; Hayhoe, FG; Rees, JK | 1 |
| Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS | 1 |
| Hamada, H; Ishida, Y; Minato, K; Ohtsu, T; Shimoyama, M; Sugimoto, Y; Tobinai, K; Tsuruo, T | 1 |
| Kyo, T; Maehama, S | 1 |
| Akahoshi, Y; Asou, N; Fujimoto, K; Fukuda, S; Ishimaru, S; Kawano, F; Murai, C; Sawatari, T; Taen, A; Takatsuki, K | 1 |
| Anger, B; Heimpel, H | 1 |
| Glisson, BS; Gupta, R; Ross, WE; Sullivan, DM | 1 |
| Kerstjens, HA; Lo, GT; Meinesz, AF; Postmus, PE; Sleijfer, DT; Sluiter, HJ | 1 |
| Ehninger, G; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Mitrou, PS; Ohl, S; Queisser, W; Schlimok, G | 1 |
| Fink, FM; Gadner, H; Grümayer, ER; Kardos, G; Revesz, T; Schuler, D | 2 |
| Budde, M; Creutzig, U; Riehm, H; Ritter, J; Schellong, G | 1 |
| Dahl, GV; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
| Amadori, S; Avvisati, G; Mandelli, F; Meloni, G; Petti, MC; Tafuri, A | 1 |
| Hill, BT; Lock, RB | 1 |
| Murray, SL; Slater, LM; Stupecky, M; Sweet, P; Wetzel, MW | 1 |
| Bishop, JF; Cobcroft, R; Dodds, A; Joshua, DE; Kronenberg, H; Lowenthal, RM; Manoharan, A; Whiteside, MG; Wolf, M | 1 |
| Bowman, A; Chessells, JM; Holtzel, H; Pinkerton, CR | 1 |
| Gray, R; Rees, JK | 1 |
| Fülle, HH; Hellriegel, KP | 2 |
| Amadori, S; Ceci, A; Comelli, A; Covelli, A; Madon, E; Mandelli, F; Masera, G; Nespoli, L; Paolucci, G; Zanesco, L | 1 |
| Carella, AM; Cerri, R; Congiu, A; Damasio, E; Gaozza, E; Giordano, D; Martinengo, M; Nati, S; Risso, M; Santini, G | 1 |
| Islam, A | 1 |
| Ehninger, G; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Mitrou, PS | 1 |
| Kobrinsky, NL; Nazeravich, DR; Seargeant, LE; Sus, CJ | 1 |
| Carella, AM; Cerri, R; Congiu, A; Frassoni, F; Giordano, D; Marmont, A; Martinengo, M; Nati, S; Risso, M; Santini, G | 1 |
| Kalyanaraman, B; Sinha, BK; Trush, MA | 2 |
| Cabanillas, F | 1 |
| Gupta, RS | 1 |
| Achterrath, W; Crooke, ST; Osieka, R; Schmidt, CG; Seeber, S | 1 |
| Cherepanova, VV; Gliasova, GA; Isaev, VG; Kaporskaia, TS; Kulikov, SM; Medvedeva, NV; Parovichnikova, EN; Rekhtman, GB; Savchenko, VG; Tikhonova, LIu | 1 |
| Davison, G; Jacobs, P; Kelly, S; McLellan, G; Pillay, Y | 1 |
| Behm, FG; Boyett, JM; Hancock, ML; Krance, RA; Mahmoud, HH; Pui, CH; Raimondi, SC; Relling, MV; Ribeiro, RC; Sandlund, JT | 1 |
| Creutzig, U; Harbott, J; Löffler, H; Ludwig, WD; Riehm, H; Ritter, J; Schellong, G; Sperling, C; Zimmermann, M | 1 |
| Burghofer, S; Chiba, P; Ecker, G; Moser, A; Richter, E; Tell, B | 1 |
| Chevrier, R; Chopineau, J; Demeocq, F; Pinon, V; Sautou, V | 1 |
| Aster, JC; Inhorn, RC; Roach, SA; Slapak, CA; Soiffer, R; Stone, RM; Tantravahi, R | 1 |
| Abe, T; Hirao, A; Kawano, Y; Okamoto, Y; Saito, S; Sato, J; Shimizu, T; Suzue, T; Takaue, Y; Watanabe, T | 1 |
| Appelbaum, FR; Bigelow, CL; Files, JC; Grever, M; Head, D; Kopecky, K; Lipschitz, DA | 1 |
| Broxterman, HJ; de Vries, EG; Kuiper, CM; Mulder, NH; Scheper, RJ; Versantvoort, CH; Withoff, S | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Lin, FR; Yao, EG | 1 |
| Eguchi, H; Ikuno, Y; Inada, H; Ishii, E; Koga, H; Matuzaki, A; Miyazaki, S; Nibu, K; Okamura, J; Ueda, K | 1 |
| Archim-Baud, E; Castaigne, S; Chastang, C; Chomienne, C; Degos, L; Fenaux, P; Fey, M; Link, H; Löwenberg, B; Sanz, M | 1 |
| Bishop, JF; Cobcroft, R; Dodds, A; Herrman, R; Joshua, DE; Laidlaw, CR; Ma, D; Matthews, JP; Szer, J; Young, G | 1 |
| Reilly, JT; Snowden, JA; Wodziński, MA | 1 |
| Antin, JH; Miller, KB; Mitus, AJ; Parsons, SK; Ryan, HF; Schenkein, DP; Wheeler, C | 1 |
| Cassileth, PA; Friedenberg, WR; Hocking, WG; Marx, JJ; Mazza, JJ; Mercier, RJ; Miller, HJ; Raich, PC; Reding, DJ; Schloesser, LL | 1 |
| Burke, PJ; Cowan, K; Jones, RJ; Karp, JE; Kaufmann, SH; Miller, CB; Schneider, E; Wendel, K; Zwelling, LA | 1 |
| Cardarelli, C; Gottesman, MM; Pastan, I; Stein, WD | 1 |
| Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B | 1 |
| Cherepanova, VV; Isaev, VG; Kaporskaia, TS; Kliasova, GA; Kulikov, SM; Medvedeva, NV; Parovichnikova, EN; Rekhtman, GB; Savchenko, VG; Tikhonova, LIu | 1 |
| Cedrych, I; Hołowiecka, B; Hołowiecki, J; Kachel, L; Krawczyk, M; Krzemień, S; Rudzka, E; Wacławik, A; Wojciechowska, M; Wojnar, J | 1 |
| Benson, E; Bishop, J; Bradstock, K; Matthews, J; Page, F | 1 |
| Corey, SJ; Gollin, SM; Locker, J; Oliveri, DR; Penchansky, L; Redner, RL; Shekhter-Levin, S | 1 |
| Christensen, IJ; Hansen, HH; Jensen, PB; Sehested, M; Vindeløv, L | 1 |
| Broxterman, HJ; Eekman, CA; Kuiper, CM; Lankelma, J; Pinedo, HM; Schuurhuis, GJ; Versantvoort, CH | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Hossfeld, DK; Shi, G; Weh, HJ | 1 |
| Almqvist, A; Hallman, H; Honkanen, T; Järvenpää, E; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Ruutu, T | 1 |
| Abe, Y; Hatanaka, T; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M | 1 |
| Chan, JC; Chan, JK; Lam, SY; Wong, KF | 1 |
| Kobayashi, K; Kyohda, K; Matano, S; Matsuda, T; Nakamura, S; Ohtake, S; Okabe, Y; Okumura, H; Yoshida, T | 1 |
| Bailey, CC; Curzon, ME; Duggal, MS; Hart, P; O'Sullivan, EA | 1 |
| Delmer, A; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 1 |
| Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K | 1 |
| Demant, EJ; Friche, E; Holm, B; Jensen, PB; Sehested, M; Sørensen, BS | 1 |
| Darbyshire, PJ; Mann, JR; Sartori, PC; Stevens, MC; Taylor, MH | 1 |
| Hirakawa, K; Horiike, S; Kaneko, H; Kashima, K; Misawa, S; Nakai, H; Nakao, M; Taniwaki, M; Ueda, Y | 1 |
| Bow, EJ; Cheang, MS; Loewen, R; Schacter, B | 1 |
| Dann, EJ; Gillis, S; Rund, D | 1 |
| Elonen, E; Jokipii, A; Lautenschlager, I; Lyytikäinen, O; Ruutu, P; Tiittanen, L | 1 |
| Mempel, K; Pfetsch, M; Reiter, A; Riehm, H; Schrappe, M; Schwab, G; Welte, K | 1 |
| Bishop, JF; Bradstock, K; Cobcroft, R; Enno, A; Fox, R; Garson, OM; Gillett, A; Herrmann, R; Joshua, D; Juneja, S; Lowenthal, RM; Matthews, JP; Page, F; Szer, J; Van Der Weyden, M; Wolf, MM; Young, GA | 1 |
| Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
| Fey, MF; Hardegger, TP; Tobler, A; von Rohr, A | 1 |
| Arthur, DC; Barnard, DR; Buckley, JD; DeSwarte, J; Dusenbery, K; Gold, S; Kalousek, D; Kobrinsky, N; Lange, BJ; Lee, JW; Neudorf, S; Sanders, J; Woods, WG | 1 |
| Cleary, ML; Davis, RE; Kamel, OW; Soslow, RA; Warnke, RA | 1 |
| Bradstock, K; Brisco, J; Enno, A; Hughes, E; McCaul, K; Morley, AA; Neoh, SH; Sykes, PJ; Szer, J | 1 |
| Grander, D; Heyman, M; Jeddi-Tehrani, M; Johansson, B; Liu, Y; Nordgren, A; Ost, A; Rasool, O; Wallberg, B | 1 |
| Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Nuessler, V; Valsamas, S; Wandt, H; Wilms, K | 2 |
| Brack, N; Ehninger, G; Fackler-Schwalbe, I; Freund, M; Geer, T; Gramatzki, M; Hübner, G; Link, H; Löffler, B; Ohl, S; Poliwoda, H; Queisser, W; Raab, M; Schneider, B; Schneider, C; Schönrock-Nabulsi, P; Wandt, H | 1 |
| Huismans, DR; Klumper, E; Loonen, AH; Ossenkoppele, GJ; Pieters, R; Rottier, A; Veerman, AJ; Westra, G | 1 |
| Kearns, P; Majumdar, G; Partridge, F; Richardson, W; Wilcox, R | 1 |
| Cattan, AR; Maung, ZT | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Chauncey, T; Demirer, T; Fefer, A; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R | 1 |
| Belotti, D; Corneo, G; Maffè, PF; Pogliani, EM; Rivolta, GF | 1 |
| Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC | 1 |
| Gonzalez-Gonzalez, A; Pinilla, J; Requena, A; Velasco, JG | 1 |
| Clark, M; Gieseler, F; Glasmacher, A; Kämpfe, D; Kunze, J; Valsamas, S; Zernak, C | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Wakita, M; Yamaguchi, T | 1 |
| Archimbaud, E; Auzanneau, G; Cony-Makhoul, P; Cordonnier, C; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Leblond, V; Marie, JP; Thomas, X; Tilly, H; Troussard, X | 1 |
| Piette, J; Piret, B | 1 |
| Flavell, RA; Lorico, A; Rappa, G; Sartorelli, AC | 1 |
| Boesen, AM; de Nully Brown, P; Grønbaek, K; Hansen, OP; Hippe, E; Hoffmann, T; Jensen, MK; Pedersen-Bjergaard, J; Storm, HH; Thorling, K | 1 |
| Burke, PJ; Gore, SD; Karp, JE; Kaufmann, SH | 1 |
| Flexner, JM; Goodman, S; Greer, JP; Stein, RS; Wolff, SN | 1 |
| Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M | 1 |
| Allouche, M; Dubrez, L; Eymin, B; Solary, E | 1 |
| Ford, PJ; Germann, UA; Harding, MW; Mason, VS; Shlyakhter, D | 1 |
| Baltes-Engler, S; Dederichs, B; Diehl, V; Engelhard, M; Engert, A; Küpper, F; Lathan, B; Reiser, M; Scheulen, ME; Schnell, R; Tesch, H; Wilhelm, M; Winterhalter, B; Wörmann, B | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Yamaguchi, T | 1 |
| Berger, W; Elbling, L; Hauptmann, E; Kokoschka, EM; Micksche, M; Vetterlein, M | 1 |
| Allione, A; Bernabei, P; Forni, G; Novelli, F; Rigamonti, L | 1 |
| Hanada, R; Hongo, T; Horikoshi, Y; Sakurai, M; Yajima, S | 1 |
| Burnett, AK; Goldstone, AH; Gray, RG; Hann, IM; Rees, JK; Stevens, RF; Wheatley, K | 1 |
| Brodsky, AL; Melero, MJ; Minissale, CJ; Sánchez Avalos, JC | 1 |
| Forman, SJ; Margolin, KA; Wright, C | 1 |
| Falaschi, A; Ochem, A; Phan, TN; Tuteja, N; Tuteja, R | 1 |
| Broxterman, HJ; Heijn, M; Lankelma, J; Wielinga, PR | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Draper, MP; Levy, SB; Modrak, DE | 1 |
| Akashi, K; Eto, T; Fujisaki, T; Gondo, H; Harada, M; Harada, N; Hayashi, S; Hirota, Y; Kinukawa, N; Makino, S; Matsuishi, E; Miyamoto, T; Mizuno, S; Murakawa, M; Nagafuji, K; Niho, Y; Ohno, Y; Okamura, T; Shibuya, T; Takamatsu, Y; Takenaka, K; Taniguchi, S; Tanimoto, K; Teshima, T; Yamasaki, K | 1 |
| Ling, V; Shapiro, AB | 1 |
| Benderra, Z; Manfait, M; Morjani, H; Trussardi, A | 1 |
| Bukh, A; Clausen, N; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T | 1 |
| Bishop, JF; Bradstock, K; Lowenthal, RM; Matthews, JP; Young, GA | 1 |
| April, F; Meneghini, V; Perona, G; Pizzolo, G; Ricetti, MM; Solero, P; Tecchio, C; Todeschini, G; Veneri, D; Zanotti, R | 1 |
| Phan, TN; Tuteja, N | 1 |
| Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF | 1 |
| Gray, RG; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Bender-Götze, C; Creutzig, U; Körholz, D; Niemeyer, C; Ritter, J; Stollmann-Gibbels, B; Zimmermann, M | 1 |
| Adachi, K; Marunouchi, T; Saito, H; Towatari, M | 1 |
| Gehl, J; Mir, LM; Skovsgaard, T | 1 |
| Bailey, C; Burrett, J; Chessells, J; Hann, I; Hill, F; Richards, S | 1 |
| Almqvist, A; Elonen, E; Hänninen, A; Jansson, SE; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Nousiainen, T; Pelliniemi, TT; Rajamäki, A; Remes, K; Ruutu, T; Timonen, T; Vilpo, J; Volin, L | 1 |
| Burke, PJ; Gore, SD; Weng, LJ | 1 |
| Davey, MW; Davey, RA; Grech, KV | 1 |
| Fukuda, H; Kunitoh, H; Saijo, N; Sekine, I | 1 |
| Geller, P; Krönke, M; Machleidt, T; Scherer, G; Schwandner, R | 1 |
| Friedenberg, WR | 1 |
| Bernasconi, C; Castagnola, C; Corso, A; Dabusti, M; Lazzarino, M; Lunghi, M; Tajana, M; Zappasodi, P | 1 |
| Feller, N; Hoekman, K; Kuiper, CM; Linn, SC; Pinedo, HM; Popp-Snijders, C; Verheul, HM; Wolthers, BG | 1 |
| Brunner, R; Filipits, M; Lechner, K; Pirker, R; Suchomel, RW; Zöchbauer, S | 1 |
| Baak, JP; Broxterman, HJ; Eekman, CA; Feller, N; Klumper, E; Kuiper, CM; Ossenkoppele, GJ; Pieters, R; Schuurhuis, GJ; van Heijningen, TH | 1 |
| Burke, PJ; Cowan, K; Gore, SD; Jones, RJ; Piantadosi, S; Weng, LJ; Zilcha, M | 1 |
| Akan, H; Arat, M; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| De La Rubia, J; Gomis, F; González-García, Y; Jarque, I; Martín, G; Pérez-Sirvent, M; Sanz, MA; Sempere, A; Senent, L | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Anami, K; Asami, K; Chin, M; Fujimoto, T; Hatae, Y; Hirota, T; Horikoshi, Y; Ito, M; Iwai, A; Kaneko, Y; Katano, N; Kataoka, S; Kikuchi, M; Koizumi, S; Miyawaki, T; Mugisima, H; Nakayama, M; Nishikawa, K; Osima, K; Suzumiya, J; Taga, T; Tanaka, A; Tsurusawa, M; Watanabe, A; Yanase, T | 1 |
| Horie, T; Masutani, M; Sawada, U; Tsujino, I; Yamazaki, T | 1 |
| Aguado, MJ; Arrieta, R; Bustos, JG; Canales, MA; Hernández-García, C; Hernández-Navarro, F | 1 |
| Mollee, PN; Rodwell, R; Taylor, D; Taylor, KM; Williams, B | 1 |
| Engels, IH; Los, M; Rossmann, E; Schulze-Osthoff, K; Wesselborg, S | 1 |
| Ehninger, G; Illmer, T; Neubauer, A; Nowak, R; Oelschlägel, U; Renner, U; Schaich, M; Subat, S; Ziegs, B | 1 |
| Isaev, VG; Khoroshko, ND; Kliasova, GA; Kulikov, SM; Maslova, ER; Ol'shanskaia, IuV; Parovichnikova, EN; Pivnik, AV; Savchenko, VG; Tikhonova, LIu | 1 |
| Adachi, K; Asou, N; Hatake, K; Hiraoka, A; Jinnai, I; Kageyama, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Matsuda, S; Minami, S; Miyawaki, S; Oh, H; Ohno, R; Ohtake, S; Omoto, E; Saito, K; Sakamaki, H; Shimazaki, C; Takahashi, M; Takeyama, K; Tamura, J; Tanimoto, M; Tsubaki, K; Yamada, O | 1 |
| Filipits, M; Geissler, K; Jäger, U; Lechner, K; Pirker, R; Pohl, G; Scheper, RJ; Stranzl, T; Suchomel, RW | 1 |
| Clément, MV; Hirpara, JL; Pervaiz, S; Ramalingam, JK | 1 |
| Bauer, E; Clark, M; Gieseler, F; Nuessler, V; Valsamas, S | 1 |
| Baer, M; Caligiuri, M; Dodge, RK; George, SL; Lee, EJ; Lemke, S; Powell, BL; Schiffer, CA; Smith, R; Szatrowski, TP | 1 |
| Hayakawa, A; Kosaka, Y; Nakamura, H; Piao, JH; Sano, K | 1 |
| Benderra, Z; Doglia, SM; Manfait, M; Morjani, H; Trussardi, A; Villa, AM | 1 |
| Eden, OB; Gibson, B; Hann, I; Hill, F; Kinsey, S; Lilleyman, J; Mitchell, C; Richards, S; Vora, A | 1 |
| Bodalski, J; Bolanowski, W; Nowak, K; Stolarska, M; Zalewska-Szewczyk, B | 1 |
| Bonnefoy-Berard, N; Ferraro, C; Prigent, AF; Quemeneur, L; Revillard, JP; Taverne, C | 1 |
| Choi, CH; Chung, MH; Jeong, JH; Kim, HS; Kim, MS; Kweon, OS; Lee, TB; Lim, DY; Min, YD; Rha, HS; You, HJ | 1 |
| Akiyama, Y; Eguchi, M; Hayashi, Y; Hosoi, G; Ishii, E; Kato, K; Koike, K; Kojima, S; Nishimura, S; Ohara, A; Okamura, J; Okimoto, Y; Sako, M; Sato, T; Tsukimoto, I; Ueda, K; Yazaki, M; Yoshikawa, T | 1 |
| Eriksen, J; Friche, E; Litman, T; Maare, C; Nielsen, D; Skovsgaard, T | 1 |
| Mori, M | 1 |
| Akiyama, H; Asou, N; Kitamura, K; Kiyoi, H; Kuriyama, K; Kusumoto, S; Minami, S; Miyawaki, S; Motoji, T; Nakano, Y; Naoe, T; Nishimura, M; Ohno, R; Saito, H; Saito, K; Shimazaki, C; Shinagawa, K | 1 |
| Borst, P; de Haas, M; Evers, R; Kool, M; Smith, AJ; van Deemter, L | 1 |
| Esche, H; Opalka, B; Parssanedjad, K; Pützer, BM; Stiewe, T | 1 |
| Hatake, K; Kobayashi, T; Kuriyama, K; Minami, S; Miyawaki, S; Ohno, R; Omoto, E; Saito, K; Tamura, J; Tanimoto, M | 1 |
| Bruno, AP; d'Orgeix, AT; Laurent, G; Lautier, D; Quillet-Mary, A | 1 |
| Berger, W; Elbling, L; Micksche, M | 1 |
| Behm, FG; Boyett, JM; Campana, D; Coustan-Smith, E; Hancock, ML; Pui, CH; Raimondi, SC; Ribeiro, RC; Rivera, GK; Rubnitz, JE; Sancho, J; Sandlund, JT | 1 |
| Huismans, DR; Pieters, R; Schuurhuis, GJ; Styczynski, J; Veerman, AJ; Wysocki, M | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Guenther, PP; Huebner, A; Neumeister, V; Parwaresch, R; Sobottka, SB; Todt, H; Weissbach, G | 1 |
| Boos, J; Creutzig, U; Feldges, A; Gadner, H; Hermann, J; Kühl, J; Niemeyer, CM; Ritter, J; Sawatzki, DB; Schwabe, D; Selle, B; Zimmermann, M | 1 |
| Bieri, S; Chapuis, B; Helg, C; Miralbell, R | 1 |
| Anderson, JJ; Angus, B; Hall, AG; Horne, CH; Lodge, AJ; McIntosh, GG; Reid, MM; Steward, M | 1 |
| Buckley, DA; du Vivier, AW; Hopster, D; Keane, FM; Mufti, GJ; Munn, SE | 1 |
| Eden, O; Gibson, B; Hann, I; Harrison, C; Harrison, G; Hill, F; Richards, S; Vora, A | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Burnett, AK; Liu Yin, JA; Rees, JK; Wheatley, K | 1 |
| Bishop, JF; Bradstock, KF; Cobcroft, RG; Dodds, AJ; Enno, A; Garson, OM; Gillett, EA; Hermann, RP; Joshua, DE; Juneja, SK; Lowenthal, RM; Ma, DD; Matthews, JP; Szer, J; Taylor, KM; Wolf, M; Young, GA | 1 |
| Kanda, Y; Mineishi, S; Murakami, J; Ogasawara, T; Saito, T; Seo, S; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K | 1 |
| Fletcher, BD; Harrison, PL; Kaste, SC; Kennedy, W; Neel, MD; Pui, CH; Razzouk, BI; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT | 1 |
| Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Glimelius, B; Kimby, E; Nygren, P | 1 |
| Akiyoshi, K; Ayukawa, H; Eguchi, H; Ishii, E; Kamizono, J; Kawakami, K; Kinukawa, N; Koga, H; Kuroda, H; Matsuzaki, A; Okamura, J; Tamai, Y; Yanai, F | 1 |
| Bown, N; Hamilton, PJ; Jackson, GH; Reid, MM; Taylor, PR; Wells, AW | 1 |
| Burnett, AK; Clark, RE; Goldstone, AH; Hutchinson, RM; Smith, AG; Wheatley, K | 1 |
| Burnett, AK; Chatters, S; Goldstone, AH; Grimwade, D; Harrison, CJ; Harrison, G; Oliver, F; Walker, H; Wheatley, K | 1 |
| Bessede, G; Gambert, P; Lizard, G; Miguet, C; Neel, D | 1 |
| Cho, S; Dawson, G; Dawson, PE | 1 |
| Eriksen, J; Litman, T; Maare, C; Nielsen, D; Skovsgaard, T | 1 |
| Baptiste, N; Chen, X; Friedlander, P; Prives, C | 1 |
| Akiyama, H; Asou, N; Kiyoi, H; Kodera, Y; Kuriyama, K; Kusumoto, S; Miyawaki, S; Motoji, T; Naoe, T; Nishimura, M; Ohno, R; Saito, H; Saito, K; Shimazaki, C; Shinagawa, K; Tagawa, Y; Ueda, R | 1 |
| Bruggers, CS; Carroll, WL; Liu, T; Moos, PJ; Perkins, SL; Raetz, E; Smith, F | 1 |
| Augery-Bourget, Y; Poindessous-Jazat, V; Robert-Lézénès, J | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Leslie, KK | 1 |
| Ballard, ET; Huang, FS; Stern, LE; Warner, BW; Zwerdling, T | 1 |
| Cañete, A; Carvajal, E; Castel, V; Fernández, JM; Verdeguer, A | 1 |
| Jun Yang, Y | 1 |
| Carstensen, EV; Jensen, LH; Jensen, PB; Langer, SW; Renodon-Corniere, A; Sehested, M; Søkilde, B; Wessel, I | 1 |
| Damon, L; Linker, C; Navarro, W; Ries, C | 1 |
| Kowalski, P; Lage, H; Scheffer, GL; Stein, U | 1 |
| Fenske, N; Morgan, MB; Sakalosky, PE | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Belleri, M; Presta, M; Ribatti, D; Vacca, A | 1 |
| Anastasi, J; Baer, MR; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Kolitz, JE; Larson, RA; Minderman, H; O'Loughlin, KL; Powell, BL; Schiffer, CA | 1 |
| Davies, JH; Evans, BA; Gregory, JW; Jenney, ME | 1 |
| Baer, M; Becknell, B; Bloomfield, CD; Caligiuri, MA; Crawford, J; Dodge, RK; Farag, SS; Fehniger, TA; George, SL; Larson, RA; Lee, EJ; Schiffer, CA; Silverman, LR | 1 |
| Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X | 1 |
| Anderson, JE; Appelbaum, FR; Balcerzak, SP; Chen, IM; Head, D; Johnson, DB; Kopecky, KJ; Luthardt, FW; Norwood, TH; O'Donnell, MR; Willman, CL | 1 |
| Aledo, A; Alonzo, TA; Buxton, AB; Kobrinsky, NL; Lange, BJ; Woods, WG | 1 |
| Borker, A; Ode, D; Yu, L | 1 |
| Crews, KR; Howard, SC; Hudson, JQ; Razzouk, BI; Ribeiro, RC; Wimmer, PS | 1 |
| Bacigalupo, A; Ferrua, MT; Gallamini, A; Ghirardo, D; Lo Nigro, C; Mattei, D; Mordini, N; Osenda, M; Viscoli, C | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Blütters-Sawatzki, R; Gossen, R; Neugebauer, M; Reiter, A; Woessmann, W | 1 |
| Aoki, Y; Cioca, DP; Kiyosawa, K | 1 |
| Adil, SN; Burney, IA; Kakepoto, GN; Khurshid, M; Zaki, S | 1 |
| Al Awadi, S; Al Shemmari, S; Bajciova, V; Mottl, H; Nemec, J | 1 |
| Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T | 1 |
| Bai, DC; Li, YN; Ma, LF; Peng, X; Wang, P; Wei, HL; Yao, XJ; Zhao, HS | 1 |
| Cetin, M; Yetgin, S | 1 |
| Allen, SL; Archer, KJ; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; de la Chapelle, A; Kolitz, JE; Larson, RA; Marcucci, G; Moore, JO; Powell, BL; Ruppert, AS; Tanner, SM; Vardiman, JW; Whitman, SP | 1 |
| Okamoto, Y; Pui, CH; Razzouk, BI; Ribeiro, RC; Shenep, JL; Srivastava, DK | 1 |
| ALBI, H; GUTIERREZ, J; NEGHME, A | 1 |
| Furuta, GT; Glickman, J; Köhler, H; Nurko, S | 1 |
| Rosoff, PM; Uram, R | 1 |
| Blijlevens, N; de Pauw, B; Donnelly, P; Levenga, H; Shirango, H; Verweij, P | 1 |
| Alonzo, TA; Aplenc, R; Arndt, C; Barnard, D; Dinndorf, P; Feig, S; Feusner, J; Gerbing, R; Lange, BJ; Seibel, N; Smith, FO; Weiman, M | 1 |
| Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S | 1 |
| Buffardi, F; D'Amico, A; De Caro, MD; Fiorillo, A; Greco, N; Maggi, G; Migliorati, R; Sabbatino, MS | 1 |
| Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G | 1 |
| Agazzi, A; Bertolini, F; Calabrese, L; Cinieri, S; Cocquio, A; Goldhirsch, A; Laszlo, D; Martinelli, G; Pruneri, G; Rabascio, C | 1 |
| Baer, MR; Bloomfield, CD; George, SL; Kolitz, JE; Larson, RA; Lee, EJ | 1 |
| Fonatsch, C; Geissler, K; Jäger, U; Knöbl, P; Lechner, K; Piribauer, M; Schwarzinger, I; Sperr, WR; Thalhammer-Scherrer, R; Valent, P; Wimazal, F | 1 |
| Blazek, B; Cerná, Z; Gajdos, P; Hak, J; Hrstková, H; Hrusák, O; Jabali, Y; Kopecná, L; Michalová, K; Procházková, D; Ptoszková, H; Sedlácek, P; Smísek, P; Starý, J; Timr, P; Tousovská, K; Vávra, V | 1 |
| Abrahams, L; du Toit, C; McDonald, A; Novitzky, N; Thomas, V | 1 |
| Abdel-Latif, ME; Ariffin, H; Ariffin, WA; Chan, LL; Lin, HP | 1 |
| Al-Izzi, M; Constantinou, J; McNicholas, TA; Nitkunan, T | 1 |
| Allen, SL; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Hoke, E; Hurd, DD; Kolitz, JE; Larson, RA; Moore, JO; Powell, BL; Shea, TC; Vardiman, JW; Velez-Garcia, E | 1 |
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Kalaycio, M | 1 |
| Chaoui, D; Legrand, O; Marie, JP; Peffault De Latour, R | 1 |
| Barnes, C; Blanchette, V; Canning, P; Greenberg, M; Price, V | 1 |
| Seiter, K | 1 |
| Böhm, A; Fonatsch, C; Geissler, K; Gisslinger, H; Jäger, U; Knöbl, P; Kyrle, PA; Lechner, K; Piribauer, M; Sperr, WR; Valent, P; Wimazal, F | 1 |
| Hofland, KF; Jensen, PB; Sehested, M; Thougaard, AV | 1 |
| Fonatsch, C; Gaiger, A; Jäger, U; Kainz, B; Schwarzinger, I; Sperr, WR | 1 |
| Bloomfield, CD; Carroll, AJ; Edwards, CG; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Sterling, LJ; Vardiman, JW | 1 |
| Lemez, P; Urbánek, V | 1 |
| Balliet, AG; Fornace, AJ; Gupta, M; Gupta, SK; Hoffman, B; Hollander, MC; Liebermann, DA | 1 |
| Barbier, M; Bignon, J; Boutonnat, J; Colle, PE; Faussat, AM; Marie, JP; Ronot, X; Thierry, J; Wdzieczak-Bakala, J | 1 |
| Danilatou, V; Kalmanti, M; Mantadakis, E; Papadhimitriou, S; Paterakis, G; Stiakaki, E | 1 |
| Ao, ZF; Chen, BA; Gao, F; Shen, HL; Xia, W; Xu, WL; Zhang, YN | 1 |
| Bader, P; Boppana, S; Dormann, S; Fisch, P; Goebel, H; Jung, A; Kontny, U; Niemeyer, C; Peters, A; Strahm, B; Werner, M | 1 |
| Bevilacqua, C; Boiocchi, M; Franceschin, A; Toffoli, G | 1 |
| Goldstone, A; Hann, I; Mitchell, C; Ramanujachar, R; Richards, S; Rowe, J; Vora, A; Webb, D | 1 |
| de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K | 1 |
| Ades, S; Gould, CJ; Jones, GK; Levy, SB; Maxfield, LF | 1 |
| Burnett, AK; Craig, JI; Littlewood, T; Milligan, DW; Wheatley, K | 1 |
| Forrest, DL; Hogge, DE; Lavoie, JC; Nantel, SH; Nevil, TJ; Savoie, ML; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Gu, C; Wells, RA; Ye, T | 1 |
| Kaneko, S; Konagai, S; Masuno, T; Sato, F; Shitan, N; Ueda, K; Yamanaka, N; Yazaki, K | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Ha, SY; Lau, YL; Shek, TW | 1 |
| Brandalise, SR; Matsuda, EI; Nowill, AE; Oliveira, SN; Rodrigues, PC; Viana, MB; Yunes, JA | 1 |
| Aoun, M; Beguin, H; Georgala, A; Husson, M; Meuleman, N; Nolard, N; Vekemans, M | 1 |
| Salonen, JH | 1 |
| Alonso Ojembarrena, A; Contra Gómez, T; Díaz Pérez, MA; García Castro, J; González-Vicent, M; Madero López, L; Pérez Martínez, A; Ramírez Orellana, M | 1 |
| Martin, PL; McLean, TW; White, MS | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Lane, SW; Marlton, P; Mollee, PN | 1 |
| Dewan, MZ; Higashihara, M; Honda, M; Horie, R; Kadin, ME; Sata, T; Shoda, M; Taira, M; Umezawa, K; Watanabe, M; Watanabe, T; Yamamoto, N | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
| Chen, YH; Hu, DN; Kuo, HK; Wu, PC; Wu, YC; Yang, PM | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Höglund, M; Nahi, H; Paul, C; Sirsjö, A; Tidefelt, U; Tina, E; Uggla, B | 1 |
| Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N | 1 |
| Arruga, F; Bracco, E; Carturan, S; Catalano, R; Cilloni, D; Defilippi, I; Iacobucci, I; Martinelli, G; Messa, E; Messa, F; Morotti, A; Nicoli, P; Panuzzo, C; Pautasso, M; Rosso, V; Saglio, G | 1 |
| Chen, J; Dong, L; Gu, LJ; Jiang, H; Pan, C; Tang, JY; Wang, YP; Xue, HL; Ye, QD; Zhou, M | 1 |
| Baer, MR; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; Kolitz, JE; Langer, C; Larson, RA; Maharry, K; Marcucci, G; Mrózek, K; Paschka, P; Powell, BL; Ruppert, AS; Whitman, SP; Zhao, W | 1 |
| Bai, CH; Kim, YD; Song, SY; Woo, HJ | 1 |
| Bleibel, WK; Cook, E; Eileen Dolan, M; Hennessy, K; Innocenti, F; Liu, W; Mirkov, S; Nagasubramanian, R; Ramírez, J; Ratain, MJ; Rosner, GL; Shukla, SJ | 1 |
| Dzhulakian, UL; Egorova, EK; Giliazitdinova, EA; Gorgidze, LA; Kaplanskaia, IB; Krasil'nikova, BB; Kravchenko, SK; Kremenetskaia, AM; Lutsenko, IN; Magomedova, AU; Mar'in, DS; Margolin, OV; Ryzhikova, NA; Samoĭlova, RS; Valiev, TT; Vinogradova, IuE; Vorob'ev, AI; Vorob'ev, IA; Zvonkov, EE | 1 |
| Abe, A; Hayasaka, K; Kawakami, K; Kawano, Y; Kumamoto, T; Nishikawa, T; Okamoto, Y; Tonooka, S | 1 |
| Alonso-Llamazares, J; Marchione, R; Ricotti, C; Romanelli, P; Shiman, M | 1 |
| Behm, FG; Campana, D; Hijiya, N; Hudson, MM; Onciu, M; Pui, CH; Razzouk, BI; Ribeiro, RC; Sandlund, JT; Zhou, Y | 1 |
| Karp, J | 1 |
| Burns, LA; D'Orazio, JA; Farhoudi, N; Kesler, MV; McBride, MT | 1 |
| Campana, D; Crews, KR; Downing, JR; Gandhi, VV; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Yang, S | 1 |
| Li, Y; Mi, Y; Qiu, L; Wang, J; Zhao, Y; Zou, D | 1 |
| Diao, S; Liu, H; Rao, Q; Wang, J; Wang, M; Xing, H; Zhang, X | 1 |
| Oksenhendler, E | 1 |
| Hou, KZ; Liu, YP; Qu, XJ; Teng, YE; Yang, XH; Zhang, JD; Zhang, Y | 1 |
| Hu, NP; Hu, XM; Li, L; Liu, C; Liu, F; Ma, R; Wang, HZ; Xiao, HY; Xu, YG; Yang, XH; Zhang, SS; Zheng, CM | 1 |
| de Bont, ES; Kamps, WA; Koetse, HA; Rings, EH; Stellaard, F; Tissing, WJ; van Vliet, MJ | 1 |
| Carrier, M; Cencic, R; Minden, M; Pelletier, J; Porco, JA; Trnkus, A | 1 |
| Amadori, S; Baila, L; de Witte, T; Di Raimondo, F; Fazi, P; Ferrara, F; Labar, B; Liso, V; Mandelli, F; Marie, JP; Marmont, F; Meloni, G; Muus, P; Petti, MC; Stasi, R; Suciu, S; Thomas, X; Vignetti, M; Willemze, R; Zittoun, R | 1 |
| Eilers, M; Illmer, T; Meyer, M; Neubauer, A; Roth, P; Rübsamen, D; Slany, R; Stabla, K; Stiewe, T | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y | 1 |
| Burnett, AK; Duncombe, A; Gibson, B; Goldstone, AH; Hills, RK; McMullin, MF; Milligan, DW; Prentice, AG; Wheatley, K | 1 |
| Chott, A; Friedrich, C; Janka-Schaub, G; Kabisch, H; Schrum, J | 1 |
| Dessalvi, P; Di Tucci, AA; Emanuele, A; Pettinau, M; Romani, C | 1 |
| Cao, F; Gilbert, GE; Heegaard, CW; Hou, J; Rasmussen, JT; Shi, J; Zhang, Y; Zhou, J | 1 |
| Cai, Y; Ling, JY; Sun, XF; Xia, Y; Yan, SL; Zhen, ZJ | 1 |
| Airewele, G; Bowman, WP; Campana, D; Cao, X; Coustan-Smith, E; Dahl, G; Degar, B; Downing, JR; Inaba, H; Lacayo, NJ; Leung, W; Meshinchi, S; Onciu, M; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Taub, J | 1 |
| Allen, SL; Baer, MR; Bloomfield, CD; DeAngelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vardiman, JW; Vij, R | 1 |
| Hansen, SH; Honoré, PH; Krogh-Madsen, M | 1 |
| Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Jeha, S; Kantarjian, H; Ouzounian, S; Pierce, S; Ravandi, F; Rytting, M | 1 |
| Deguchi, T; Fujita, Y; Ito, M; Kojima, K; Nozawa, Y | 1 |
| Asano, S; Funayama, K; Murai, F; Nomura, H; Shimane, M | 1 |
| Cros-Perrial, E; Demangel, D; Dreano, M; Dumontet, C; Herveau, S; Jordheim, LP; Keime, C; Plesa, A; Vendrell, JA | 1 |
| Briel, J; Gocke, CD; Hess, AD; Kanakry, CG; Karp, JE; Kos, F; Levitsky, H; Luznik, L; Meyer, C; Smith, BD; Thoburn, C | 1 |
| Baer, MR; Bloomfield, CD; Caligiuri, MA; George, SL; Kolitz, JE; Larson, RA; Moore, JO; Mrózek, K; Powell, BL; Sanford, BL; Stone, RM | 1 |
| Pham, XH; Tran, NQ; Tuteja, N; Tuteja, R | 1 |
| Agrawal, AK; Golden, C; Guo, H | 1 |
| Czarnik-Matusewicz, H; Ganczarski, G; Gąsiorowski, J; Głowacka, K; Kuliczkowski, K; Orzechowska-Juzwenko, K; Wiela-Hojeńska, A; Wołowiec, D; Łapiński, Ł | 1 |
| Cox, NJ; Dolan, ME; Gamazon, ER; Huang, RS | 1 |
| Belinka, BA; Gupta, A; Kachlany, SC; Le, A | 1 |
| Ahmad, J; Hussain, G; Kausar, S; Zafar, L | 1 |
| Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO | 1 |
| De Graaf, SS; Gibson, BE; Harrison, CJ; Howman, AJ; Webb, DK; Wheatley, K | 1 |
| Bain, BJ; Innes, A; May, PC; Pavlů, J | 1 |
| Khapre, RV; Kondratov, RV; Kondratova, AA; Susova, O | 1 |
| Balci, TB; Berman, JN; Buck, SA; Dellaire, G; Dombkowski, AA; Edwards, H; Ge, Y; Matherly, LH; Taub, JW; Xavier, AC; Xie, C | 1 |
| Bender, B; Friberg, LE; Honoré, PH; Jensen, MK; Krogh-Madsen, M; Nielsen, OJ | 1 |
| Atenafu, EG; Brandwein, JM; Gupta, V; Minden, MD; Murray, C; Nixon, S; Saini, L; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Avilia, S; Battipaglia, G; Camera, A; Caranci, F; Morelli, E; Perna, F | 1 |
| Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
| Dang, NH; Ghani, FI; Iwata, S; Morimoto, C; Naito, M; Yamazaki, H | 1 |
| Alonzo, TA; Arceci, RJ; Barnard, D; Gamis, AS; Gerbing, RB; Hathaway, L; Hilden, JM; Loew, TW; Ravindranath, Y; Smith, FO; Sorrell, AD; Taub, JW; Woods, WG | 1 |
| Atkinson, HD; Colovic, M; Colovic, N; Jankovic, G; Kraguljac, N; Radojkovic, M; Stanisavljevic, D; Suvajdzic, N; Tomin, D; Vidovic, A | 1 |
| Appelbaum, FR; Geraghty, DE; Godwin, JE; Ho, PA; Kutny, M; Meshinchi, S; Ostronoff, F; Othus, M; Petersdorf, SH; Radich, JP; Stirewalt, DL; Willman, CL | 1 |
| Colovic, M; Floros, KV; Gourgiotis, D; Pavlovic, S; Scorilas, A; Thomadaki, H; Tosic, N | 1 |
| Alonzo, TA; Aplenc, R; Gamis, AS; Gerbing, RB; Sung, L | 1 |
| Abella, E; Amigo, ML; Barrios, M; Bravo, P; Brunet, S; García, O; González-Campos, J; Hernández-Rivas, JM; Montesinos, P; Ribera, JM | 1 |
| Colovic, N; Djunic, I; Djurasinovic, V; Jankovic, G; Palibrk, V; Suvajdzic, N; Tomin, D; Vidovic, A; Virijevic, M | 1 |
| Czyzewski, K; Debski, R; Jaworska-Posadzy, A; Kolodziej, B; Kubicka, M; Kurylo-Rafinska, B; Piatkowska, M; Pogorzala, M; Styczynski, J; Wysocki, M | 1 |
| Atenafu, EG; Brandwein, JM; Gupta, V; Hassanein, M; Minden, MD; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Aplenc, R; Bagatell, R; Fisher, BT; Huang, YS; Kavcic, M; Lee, GE; Li, Y; Seif, AE; Tasian, SK; Torp, K; Vujkovic, M; Walker, DM | 1 |
| Berger, W; Filipits, M; Glimm, H; Hackl, H; Hartl, K; Heffeter, P; Heilos, D; Hemmati, S; Herbacek, I; Herbst, F; Karakaya, K; Krämer, A; Rommer, A; Rondou, P; Schwarzinger, I; Steinleitner, K; Steinmetz, B; Wieser, R | 1 |
| Creutzig, U; Dworzak, MN; Reinhardt, D; Ritter, J; Schellong, G; Zimmermann, M | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Bowman, WP; Campana, D; Coustan-Smith, E; Dahl, G; Inaba, H; O'Hear, C; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shi, L; Taub, JW | 1 |
| Amadori, S; Beksac, M; Berneman, Z; Bron, D; Camera, A; Cantore, N; Cilloni, D; de Witte, T; Fabbiano, F; Fazi, P; Fillet, G; Guimaraes, JE; Hagemeijer, A; Halkes, CJ; Jansen, J; Labar, B; Lefrère, F; Leoni, P; Luppi, M; Magro, D; Mancini, M; Mandelli, F; Marie, JP; Marijt, EW; Meert, L; Melillo, L; Meloni, G; Mistrik, M; Mitra, ME; Muus, P; Nobile, F; Sborgia, M; Selleslag, DL; Sica, S; Specchia, G; Suciu, S; Thomas, X; Trisolini, SM; Venditti, A; Vignetti, M; Willemze, R | 1 |
| Allen, SL; Bakan, CE; Benson, DM; Bloomfield, CD; Caligiuri, MA; Deangelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vij, R | 1 |
| Miyawaki, S | 1 |
| Su, Y; Zhang, L; Zhang, R; Zhou, X | 1 |
| Ahmad, M; Tabassum, F; Tarique, M; Tuteja, R | 1 |
| Baik, H; Bossis, G; Boutzen, H; Brockly, F; Kaoma, T; Kifagi, C; Manenti, S; Pelegrin, M; Piechaczyk, M; Récher, C; Ristic, M; Saland, E; Salem, T; Sarry, JE; Vallar, L; Vergez, F | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Fu, WM; Hsieh, IS; Yang, RS | 1 |
| Amadori, S; Arcese, W; Buccisano, F; Cerretti, R; De Angelis, G; Del Principe, MI; Di Veroli, A; Ditto, C; Irno-Consalvo, M; Lo-Coco, F; Maurillo, L; Nasso, D; Panetta, P; Piciocchi, A; Refrigeri, M; Sarlo, C; Sconocchia, G; Venditti, A | 1 |
| DeFilippis, EM; Gaan, J; Garshick, M; Harp, J | 1 |
| Alonzo, TA; Aplenc, R; Bagatell, R; Fisher, BT; Gamis, A; Gerbing, RB; Hall, M; Huang, YS; Li, Y; Luger, S; Miller, TP; Rubin, D; Seif, AE; Sung, L; Torp, K; Troxel, AB | 1 |
| Gill Super, HJ | 1 |
| de Jong, J; Neefjes, J; Pang, B; Qiao, X; Wessels, LF | 1 |
| Alebouyeh, M; Faranoush, M; Hedayati Asl, AA; Mehrvar, A; Niktoreh Mofrad, N; Reinhardt, D; Tashvighi, M | 1 |
| Bae, SH; Chi, HS; Eom, HS; Hyun, MS; Jang, DY; Joo, YD; Jung, CW; Kim, DY; Kim, H; Kim, HJ; Kim, I; Kim, MK; Lee, GW; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, S; Ryoo, HM; Shin, HJ; Sohn, SK; Won, JH; Yang, DH; Yun, SC | 1 |
| Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S | 1 |
| Chauhan, M; Tarique, M; Tuteja, R | 1 |
| Kobos, R; LaQuaglia, MP; Modak, S; Pandit-Taskar, N; Sait, S | 1 |
| Beltrão, EI; Benicio, MT; Bezerra, MA; Bezerra, MF; Coelho-Silva, JL; Lucena-Araujo, AR; Machado, CG; Nascimento, JC; Rego, EM; Rocha, CR | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Killian-Benigno, C; Kuo, DJ | 1 |
| Cuglievan, B; Garces, S; Menegaz, BA; Rytting, ME | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Bertolini, F; Cassisa, A; Gasparin, P; Miggiano, MC | 1 |
| Chmielewska, K; Kluska, M; Pietrzak, J; Robaszkiewicz, A; Rygielska, Ż; Tempka, D; Tokarz, P; Virág, L | 1 |
| Bruckner, T; Hensel, M; Ho, AD; Kriegsmann, K; Kriegsmann, M; Rieger, M; Schwarzbich, MA; Sitter, S; Witzens-Harig, M; Wuchter, P | 1 |
| Houssou, B; Lamchahab, M; Massi, R; Oukkache, B; Quessar, A | 1 |
| Adamkiewicz-Drożynska, E; Bączek, T; Bień, E; Kowalski, P; Krawczyk, MA; Maliszewska, O; Miękus, N; Olędzka, I; Plenis, A | 1 |
| Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
| Chang, YT; Ghiaur, G; Hernandez, D; Jones, RJ; Su, M | 1 |
| Bakhshi, R; Bakhshi, S; Pramanik, R; Singh, A; Tyagi, A; Vishnubhatla, S | 1 |
| Bakhshi, S; Chopra, A; Ganguly, S; Garg, A; Vishnubhatla, S | 1 |
| Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR | 1 |
| Abe, K; Dowsett, L; Hutchins, K; Wada, R | 1 |
| Abdelhafiz, A; Elfishawi, S; Gameel, A; Ibraheem, D; Kamel, A; Madney, Y; Osman, R; Radwan, E; Rasekh, EO | 1 |
| Burnett, AK; Clark, RE; Drummond, M; Freeman, S; Hills, RK; Huntly, B; Kell, J; Kjeldsen, L; Knapper, S; McMullin, MF; Russell, NH; Spearing, R; Thomas, IF | 1 |
| Kapoor, R; Rastogi, N; Sarma, S; Thakkar, D; Wadhwa, T; Yadav, SP | 1 |
| Al-Mansour, Z; Alonzo, TA; Aplenc, R; Cao, X; Cogle, C; Elsayed, AH; Gamis, A; Kolb, EA; Lamba, JK; Meshinchi, S; Mitra, AK; Pounds, S; Raimondi, S; Ribeiro, RC; Rubnitz, J; Wu, H | 1 |
| Kakikawa, M; Shibaki, R | 1 |
| Bojalil-Álvarez, L; Cortés, JE; Fernández-Gutiérrez, JA; García-Villaseñor, E; Murrieta-Álvarez, I; Reyes-Cisneros, OA; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Sánchez-Bonilla, D | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
27 review(s) available for daunorubicin and etoposide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Monocytic, Acute; Neoplasms, Germ Cell and Embryonal; Remission Induction; Sacrococcygeal Region; Time Factors | 1991 |
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Topics: Amsacrine; Animals; Antineoplastic Agents; Camptothecin; Cricetinae; Daunorubicin; DNA Replication; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Humans; Mice; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1991 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
Monosomy 7 syndrome in an infant with neurofibromatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 7; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Diagnosis, Differential; Etoposide; Humans; Infant; Leukemia, Myelomonocytic, Chronic; Male; Monocytes; Monosomy; Neurofibromatosis 1; Pedigree; Preleukemia; Syndrome; Thioguanine | 1991 |
Cell kinetics as related to treatment of patients with acute nonlymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Cycle; Child; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hydrocortisone; Leukemia; Methotrexate; Mitotic Index; Neoplastic Stem Cells; Prednisone; Prognosis; Vincristine | 1985 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Eosinophilia; Etoposide; Fatal Outcome; Female; Humans; Hydroxyurea; Hyperplasia; Ifosfamide; Leukemia, Myeloid; Lymph Nodes; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Syndrome; Translocation, Genetic; Vincristine | 1995 |
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Differentiation; China; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Europe; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocytosis; Life Tables; Middle Aged; Mitoxantrone; New York; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 1995 |
Toxic megacolon complicating chemotherapy for acute myeloid leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Megacolon, Toxic | 1994 |
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Remission Induction | 1998 |
Cancer chemotherapy in the elderly.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Busulfan; Daunorubicin; Doxorubicin; Etoposide; Female; Fluorouracil; Heart; Hematologic Neoplasms; Humans; Lung; Male; Middle Aged; Neoplasms; Pyrazoles | 1998 |
[Acute myelogenous leukemia in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quality of Life; Remission Induction | 2000 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2001 |
Successful chemotherapy for melanotic neuroectodermal tumor of infancy in a baby.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Daunorubicin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Maxillary Neoplasms; Neuroectodermal Tumor, Melanotic; Treatment Outcome; Vinca Alkaloids | 2003 |
Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxyadenosines; Double-Blind Method; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hypotension; Immunocompromised Host; Leukemia, Myeloid; Male; Mycoses; Neutropenia; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Retrospective Studies; Sepsis; Streptococcal Infections; Viridans Streptococci | 2003 |
Fatal hemorrhagic pneumonia caused by infection due to Kytococcus sedentarius--a pathogen or passenger?
Topics: Actinomycetales; Actinomycetales Infections; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Translocation; Cefepime; Cephalosporins; Clostridium Infections; Colistin; Cytarabine; Daunorubicin; Drug Therapy, Combination; Etoposide; Fatal Outcome; Hemoptysis; Humans; Hydroxyurea; Immunocompromised Host; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Metronidazole; Middle Aged; Neutropenia; Pneumonia, Bacterial; Superinfection; Teicoplanin; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
Testicular granulocytic sarcoma, a source of diagnostic confusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleus; Cyclophosphamide; Cytarabine; Cytoplasmic Granules; Daunorubicin; Diagnosis, Differential; Diagnostic Errors; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisolone; Sarcoma, Myeloid; Testicular Neoplasms; Vincristine | 2004 |
Toxicity of the topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Epirubicin; Etoposide; Humans; Idarubicin; Leukemia; Middle Aged; Mitoxantrone; Mucositis; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors; Vascular Diseases | 2005 |
Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
Topics: Adenoma, Sweat Gland; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carcinoma, Acinar Cell; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Male; Mercaptopurine; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Parotid Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survivors; Sweat Gland Neoplasms; Vincristine; Whole-Body Irradiation | 2008 |
CD4+/CD56+ Hematodermic neoplasm (plasmacytoid dendritic cell tumor).
Topics: Antineoplastic Combined Chemotherapy Protocols; CD4 Antigens; CD56 Antigen; Cyclophosphamide; Daunorubicin; Dexamethasone; Doxorubicin; Etoposide; Humans; Immunophenotyping; Killer Cells, Natural; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Pruritus; Remission Induction; Vincristine | 2008 |
HIV-associated multicentric Castleman disease.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Asparaginase; Castleman Disease; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Ganciclovir; Herpesviridae Infections; Herpesvirus 8, Human; HIV Infections; Humans; Lymph Nodes; Rituximab; Thioguanine; Valganciclovir; Virus Replication | 2009 |
Development of a curative treatment within the AML-BFM studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Methotrexate; Multicenter Studies as Topic; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thioguanine; Vincristine | 2013 |
[Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Discovery; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Mutation; Recurrence; Tretinoin; Vincristine | 2014 |
[Report of a case with secondary acute promyelocytic leukemia after therapy for hemophagocytic lymphohistiocytosis and review of literature].
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Daunorubicin; Epstein-Barr Virus Infections; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Lymphohistiocytosis, Hemophagocytic; Male; Neoplasms, Second Primary; Risk Assessment; Treatment Outcome; Tretinoin | 2013 |
A role for epigenetics in the formation of chromosome translocations in acute leukemia.
Topics: Chromatin Assembly and Disassembly; Daunorubicin; DNA Breaks, Double-Stranded; Epigenesis, Genetic; Etoposide; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Myeloid-Lymphoid Leukemia Protein; Translocation, Genetic | 2015 |
138 trial(s) available for daunorubicin and etoposide
| Article | Year |
|---|---|
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction | 1992 |
Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors | 1992 |
Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age. A Southwest Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 1992 |
Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid; Recurrence; Remission Induction; Thioguanine; United Kingdom | 1992 |
A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Thioguanine; Time Factors | 1992 |
Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine; Vincristine | 1990 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival Analysis | 1991 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Daunorubicin; Etoposide; Follow-Up Studies; Graft vs Host Disease; Humans; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Time Factors; Transplantation, Homologous; Vincristine; Whole-Body Irradiation | 1991 |
Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; New Zealand; Remission Induction; Survival Rate | 1991 |
Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Thioguanine; Vindesine | 1991 |
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Denmark; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Regression Analysis; Remission Induction; Survival Rate | 1991 |
[Intensification of chemotherapy of acute myeloid leukemia in children: report on the studies of the AML-BFM 78 and AML-BFM 83 protocols].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Prognosis; Remission Induction; Thioguanine; Time Factors; Vincristine | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Remission Induction | 1991 |
Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Infant; Leukemia, Myeloid, Acute; Life Tables; Multicenter Studies as Topic; Remission Induction; Thioguanine | 1990 |
Therapy of acute myelogenous leukemia in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Italy; Leukemia, Myeloid, Acute; Life Tables; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine | 1990 |
Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Survival Rate | 1990 |
Treatment of relapsed acute lymphocytic leukemia in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Brain Neoplasms; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Germany, West; Humans; Ifosfamide; Leucovorin; Life Tables; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Spinal Cord Neoplasms; Teniposide; Testicular Neoplasms; Vindesine | 1990 |
Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Multivariate Analysis; Prognosis; Risk Factors | 1990 |
The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Pilot Projects; Random Allocation; Remission Induction; Thioguanine | 1990 |
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Survival Analysis | 1990 |
Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male | 1986 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation; Remission Induction; Risk; Thioguanine; United Kingdom | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; England; Etoposide; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Infections; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia | 1988 |
Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes; Prospective Studies; Remission Induction | 1987 |
The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Methotrexate; Prednisone; Prognosis; Remission Induction; Risk; Thioguanine; Vincristine | 1987 |
A comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vincristine | 1987 |
Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Thioguanine; Vincristine | 1987 |
[Risk groups in acute, non-lymphatic leukemia in childhood. Analysis of the results of the cooperative therapeutic studies AML-BFM 78 and 83].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prognosis; Risk; Thioguanine | 1986 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoguazone; Recurrence | 1981 |
[The results of 2 and 1/2 years of work of the Russian Multicenter Trial on the Treatment of Acute Myeloid Leukemias in Adults].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Remission Induction; Russia; Survival Analysis; Time Factors | 1995 |
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Humans; Infant; Karyotyping; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 1995 |
Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
Topics: Acute Disease; Adolescent; Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Chromosome Aberrations; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Immunophenotyping; Infant; Leukemia, Myeloid; Neoplastic Stem Cells; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Sensitivity and Specificity; Treatment Outcome | 1995 |
Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Thioguanine; United States | 1995 |
Etoposide-based combination chemotherapy in malignant histiocytosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Etoposide; Female; Histiocytic Sarcoma; Humans; Male; Middle Aged; Prednisone; Remission Induction | 1994 |
[Treatment results of acute nonlymphocytic leukemia in childhood--Kyushu Yamaguchi Children's Cancer Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Recurrence; Remission Induction; Survival Rate; Vincristine | 1995 |
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Differentiation; China; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Europe; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocytosis; Life Tables; Middle Aged; Mitoxantrone; New York; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 1995 |
The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukemia. Australian Leukemia Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Myeloid, Acute; Life Tables; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Treatment Outcome | 1994 |
Improved survival for patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; United States | 1995 |
The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Infusions, Intravenous; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Rate | 1995 |
[The results of a multicenter cooperative study on treating acute myeloid leukemias in adults].
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Russia | 1994 |
[Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome | 1994 |
Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Etoposide; Follow-Up Studies; HLA-DR Antigens; Humans; Immunophenotyping; Leukemia; Middle Aged; Predictive Value of Tests; Prognosis; Survival Analysis; Time Factors | 1994 |
Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid; Male; Remission Induction; Thioguanine | 1994 |
[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Granisetron; Humans; Indazoles; Lymphoma; Male; Middle Aged; Mitoxantrone; Nausea; Vomiting | 1993 |
A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Fever; Filgrastim; Gastrointestinal Diseases; Germany; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Infant; Infection Control; Life Tables; Male; Mercaptopurine; Methotrexate; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prospective Studies; Recombinant Proteins; Risk; Survival Analysis; Thioguanine; Vincristine; Vindesine | 1996 |
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Diseases; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Eye Diseases; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Life Tables; Male; Prospective Studies; Remission Induction; Survival Analysis; Survival Rate; Thioguanine; Treatment Outcome | 1996 |
Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Mercaptopurine; Methotrexate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Survival Analysis; Treatment Outcome; Vincristine | 1996 |
[Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome | 1996 |
Anthracycline drugs and MDR expression in human leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
[Treatment results for unselected patients with acute myelogenous leukemia. During a 10-year period, August 1984 to July 1994].
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Patient Selection; Prednisolone; Remission Induction; Retrospective Studies; Treatment Outcome | 1996 |
Timed sequential chemotherapy for advanced acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1996 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Survival Rate; Survivors | 1997 |
Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Remission Induction; Tumor Cells, Cultured | 1996 |
Etoposide and mitoxantrone as a second cycle of consolidation therapy following high dose cytosine arabinoside and daunorubicin in patients with acute non-lymphocytic leukemia in remission: a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Salvage Therapy | 1996 |
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Individuality; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1997 |
[Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Time Factors; Vinblastine; Vincristine | 1997 |
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medica
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Hydrocortisone; Infant; Leukemia, Myeloid; Life Tables; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome | 1997 |
[Chemotherapy schedules and bacteremia in adult patients with acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Daunorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Male; Mitoxantrone; Neutropenia; Risk Factors | 1996 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome | 1997 |
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Remission Induction | 1998 |
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 1998 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Patient Compliance; Recurrence; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 1998 |
Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Infant, Newborn; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Thioguanine; Vincristine | 1998 |
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Prospective Studies; Remission Induction; Vincristine | 1998 |
Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cell Line; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunophenotyping; Infusions, Intravenous; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Growth Factor; Remission Induction | 1995 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1998 |
[Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
Topics: Adolescent; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Vincristine | 1998 |
[Results of clinical trials in the treatment of acute myeloid leukemia in adults during a 7-year period].
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Time Factors; Treatment Outcome | 1999 |
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis | 1999 |
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia g
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1999 |
Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infections; Male; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2000 |
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Probability; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2000 |
Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA Mutational Analysis; Etoposide; Female; Gene Deletion; Genes, p53; Humans; Japan; Leukemia, Myeloid; Life Tables; Male; Mercaptopurine; Middle Aged; Mutation; Mutation, Missense; Neoplasm Proteins; Prednisolone; Prognosis; Regulatory Sequences, Nucleic Acid; Single-Blind Method; Survival Analysis; Tumor Suppressor Protein p53; Vincristine | 2000 |
[Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group].
Topics: Adolescent; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Prospective Studies | 2000 |
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Treatment Outcome | 2001 |
Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome.
Topics: Adolescent; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Infant; Infant, Newborn; Isoenzymes; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Topoisomerase II Inhibitors; Treatment Outcome | 2001 |
Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Chromosome Aberrations; Chromosome Disorders; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Humans; Infant; Leukocyte Count; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Remission Induction; Risk Factors; Sex Factors; Thioguanine; United Kingdom; Vincristine | 2001 |
Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 2001 |
Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Infusions, Intravenous; Injections, Intravenous; Life Tables; Male; Methotrexate; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vincristine | 2001 |
Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Immunophenotyping; Infant; Male; Mercaptopurine; Methotrexate; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Risk; Risk Factors; Severity of Illness Index; Sex Factors; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon-alpha; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; United Kingdom; Vincristine | 2001 |
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon-alpha; Karyotyping; Lenograstim; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Predictive Value of Tests; Prednisone; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; United Kingdom; Vincristine | 2001 |
Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Follow-Up Studies; Gene Deletion; Genotype; Glutathione Transferase; Humans; Isoenzymes; Leukemia, Myeloid; Mercaptopurine; Multivariate Analysis; NAD(P)H Dehydrogenase (Quinone); Neoplasm Proteins; Peroxidase; Polymorphism, Genetic; Prednisolone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Remission Induction | 2002 |
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Fatigue; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Immunologic Factors; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Life Tables; Middle Aged; Nausea; Neoplasm Proteins; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Immunologic; Receptors, Natural Killer Cell; Recombinant Fusion Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction | 2002 |
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Hyperbilirubinemia; Infection Control; Length of Stay; Leukemia, Myeloid; Male; Neutropenia; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Thrombocytosis; Treatment Outcome | 2002 |
The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Methotrexate; Methylprednisolone; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2003 |
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Genetic Markers; Genetic Predisposition to Disease; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Treatment Outcome | 2003 |
Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2004 |
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2004 |
[Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male | 2004 |
Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
Induction chemotherapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Risk Factors; Survival Analysis; Treatment Outcome | 2005 |
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Cytarabine; Daunorubicin; Etoposide; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Recurrence | 2006 |
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Mitoxantrone; Thioguanine; Treatment Outcome; United Kingdom | 2006 |
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Tretinoin | 2006 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Young Adult | 2009 |
Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberrations; Cytarabine; Daunorubicin; Drugs, Chinese Herbal; Etoposide; Female; Humans; Immunophenotyping; Integrative Medicine; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Treatment Outcome; Young Adult | 2009 |
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carbohydrates; Cell Death; Child; Child, Preschool; Citrulline; Cytarabine; Daunorubicin; DNA; Enterocytes; Etoposide; Feces; Female; Humans; Infant; Interleukin-8; Intestinal Absorption; Leukemia, Myeloid; Leukocyte L1 Antigen Complex; Male; Mitoxantrone; Models, Biological; Mucositis; Stomatitis | 2009 |
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Thioguanine; Treatment Outcome; Tretinoin; Young Adult | 2010 |
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Remission Induction; Survival Rate; Young Adult | 2010 |
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine | 2010 |
Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.
Topics: Acetylation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytochrome P-450 CYP2D6; Daunorubicin; Drug Interactions; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Oxidation-Reduction; Phenotype; Young Adult | 2011 |
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Survival Analysis; Thioguanine; Treatment Outcome | 2011 |
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Chromatography, High Pressure Liquid; Creatinine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Prospective Studies; Tissue Distribution; Young Adult | 2012 |
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Down Syndrome; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2012 |
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Etoposide; Exons; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Leukocytosis; Male; Survival Rate | 2012 |
Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Imatinib Mesylate; Male; Mercaptopurine; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vincristine; Young Adult | 2012 |
Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Cell Count; Bone Marrow Cells; Comorbidity; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hemoglobins; Humans; Immunophenotyping; Kaplan-Meier Estimate; Karyotyping; Kidney Function Tests; Leukemia, Myeloid, Acute; Liver Function Tests; Logistic Models; Male; Middle Aged; Prognosis; Remission Induction; Risk Factors; Treatment Outcome | 2012 |
High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Risk Factors; Survival Rate | 2013 |
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Survival Analysis; Treatment Outcome | 2013 |
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Survival Analysis | 2015 |
Family History and Relapse in Pediatric Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Rate | 2015 |
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Vincristine | 2015 |
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 2016 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Recurrence; Survival Rate | 2020 |
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nucleophosmin; Prognosis; Survival Rate; Young Adult | 2021 |
324 other study(ies) available for daunorubicin and etoposide
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Formazans; Glioma; Rats; Tubulin; Tumor Cells, Cultured | 1996 |
Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport.
Topics: Adenosine Triphosphate; Anthracyclines; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport; Cell Membrane; Daunorubicin; Glutathione; Humans; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1997 |
Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Cells, Cultured; Culture Techniques; Drug Resistance, Neoplasm; Embryo, Mammalian; Estradiol; Glutathione; Humans; Isomerism; Kidney; Leukotriene C4; Membranes; Mice; Multidrug Resistance-Associated Proteins; Phenotype; Transfection; Vincristine | 1997 |
A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Biological Transport, Active; Caco-2 Cells; Drug Interactions; Humans; Ligands; Models, Theoretical; Paclitaxel; Tritium | 2001 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Digoxin; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Genes, MDR; Humans; Intestinal Mucosa; Transfection | 2002 |
Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?
Topics: Animals; Caco-2 Cells; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Intestinal Mucosa; Mitochondrial Proteins; Multidrug Resistance-Associated Protein 2; Ribosomal Proteins; Saccharomyces cerevisiae Proteins; Transfection; Vinblastine | 2002 |
Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).
Topics: Animals; Antineoplastic Agents; Biological Transport, Active; CHO Cells; Cricetinae; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Leukotriene C4; Multidrug Resistance-Associated Proteins; Teniposide; Transfection | 2002 |
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Neoplasms, Experimental; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Antibiotics, Antineoplastic; Cell Line, Transformed; Cloning, Molecular; Dogs; Drug Resistance, Multiple; Humans; Kidney; Leukotriene C4; Macaca fascicularis; Mice; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; RNA, Messenger; Sequence Homology, Amino Acid; Species Specificity; Transfection | 2003 |
Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1).
Topics: Amino Acid Sequence; Animals; Carrier Proteins; Cell Line; Cloning, Molecular; DNA, Complementary; Doxorubicin; Embryo, Mammalian; Estradiol; Estradiol Congeners; Estrone; Gene Expression Regulation; Humans; Kidney; Leukotriene C4; Mice; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Amino Acid; Species Specificity; Substrate Specificity; Transfection; Tritium | 2003 |
Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.
Topics: Antineoplastic Agents; Apoptosis; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Isomerism; Resveratrol; Stilbenes; Structure-Activity Relationship; Tumor Cells, Cultured | 2003 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one.
Topics: Apoptosis; Azepines; G1 Phase; HL-60 Cells; Humans; K562 Cells; Molecular Structure; Pyrazoles; Resting Phase, Cell Cycle | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
Topics: Amino Acids; Antineoplastic Agents; Arginine; Cell Line, Tumor; DNA; DNA Topoisomerases, Type II; Humans; Indenes; Isoquinolines; Mutation; Structure-Activity Relationship; Topoisomerase II Inhibitors; Transition Temperature | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Isoquinolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transition Temperature | 2011 |
Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; K562 Cells; Molecular Structure; Pyrazoles; Structure-Activity Relationship | 2015 |
Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV.
Topics: Adult; Antineoplastic Agents; Azirines; Bleomycin; Cyclophosphamide; Daunorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Prednisone; Procarbazine; Teniposide; Triethylenemelamine; Vinblastine; Vincristine | 1975 |
The therapy of acute leukemia in the adult: a progress report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin | 1976 |
Anthracycline cardiomyopathy in children: report of two cases.
Topics: Child; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Heart Failure; Humans; Infant; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Microscopy, Electron; Myofibrils | 1979 |
Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; Leukemia L1210; Male; Mercaptopurine; Methotrexate; Mice; Mice, Inbred DBA; Podophyllotoxin; Vincristine | 1976 |
[The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination].
Topics: Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Thioguanine; Vincristine | 1976 |
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Cell Membrane Permeability; Daunorubicin; Drug Resistance; Energy Metabolism; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Nigericin; Phenotype; RNA, Messenger; Tumor Cells, Cultured; Vincristine | 1992 |
Patchy polyneuropathy in acute promyelocytic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cytarabine; Daunorubicin; Disseminated Intravascular Coagulation; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Male; Paraneoplastic Syndromes; Peripheral Nervous System Diseases; Remission Induction; Translocation, Genetic; Transplantation, Homologous | 1992 |
Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis.
Topics: Amsacrine; Camptothecin; Chromosome Aberrations; Chromosomes, Human; Daunorubicin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Ellipticines; Ethidium; Etoposide; Humans; In Vitro Techniques; Lymphocytes; Mitosis; Mitoxantrone; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1992 |
Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.
Topics: Animals; CHO Cells; Chromosome Mapping; Chromosomes, Human, Pair 17; Colony-Forming Units Assay; Cricetinae; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; DNA, Single-Stranded; Doxorubicin; Etoposide; Genes; Humans; Hybrid Cells; Mitoxantrone | 1992 |
Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice.
Topics: Alkaloids; Animals; Antibodies, Monoclonal; Daunorubicin; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Immunotoxins; Leukocyte Count; Mice; Mice, Transgenic; Paclitaxel; Pseudomonas aeruginosa; Vinblastine; Vincristine | 1992 |
Case report: alternation therapy with antileukemic agents and recombinant human granulocyte colony-stimulating factor for RAEB in transformation.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged | 1992 |
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine | 1992 |
DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis | 1992 |
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Cause of Death; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Norway; Recurrence; Remission Induction; Survival Analysis; Survival Rate; Thioguanine | 1992 |
Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Macrophage Colony-Stimulating Factor; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Predictive Value of Tests; Prednisone; Remission Induction; Vindesine | 1992 |
Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clone Cells; Cytarabine; Daunorubicin; DNA, Neoplasm; Etoposide; Female; Genetic Linkage; Humans; Leukemia, Promyelocytic, Acute; Translocation, Genetic; Tretinoin; X Chromosome | 1992 |
Relationship of VP-16 to the classical multidrug resistance phenotype.
Topics: Affinity Labels; Animals; Carbon Radioisotopes; Carcinoma, Ehrlich Tumor; Cell Membrane; Cell Nucleus; Daunorubicin; Drug Resistance; Etoposide; Phenotype; Polysorbates; Tumor Cells, Cultured; Verapamil | 1992 |
Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells.
Topics: Blotting, Northern; Cyclophosphamide; Daunorubicin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Gene Expression; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Recombinant Proteins; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1990 |
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Topics: Amsacrine; Aphidicolin; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Cycloheximide; Daunorubicin; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA Polymerase II; DNA Replication; Drug Synergism; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Mutagens; RNA; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1991 |
Novel translocation (2;4) with consistent involvement of 2p23 in acute nonlymphocytic leukemia (M2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 4; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Translocation, Genetic | 1992 |
Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Vindesine | 1992 |
Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leuke
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Vinca Alkaloids | 1991 |
[Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Life Tables; Male; Methotrexate; Mitoxantrone; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1991 |
Response to trans-retinoic acid in an AMLM3 patient resistant to cis-retinoic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Lomustine; Male; Middle Aged; Stereoisomerism; Tretinoin | 1991 |
Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein.
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenites; Blotting, Western; Carmustine; Cell Line; Cell Survival; Colchicine; Cricetinae; Dactinomycin; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Fluorouracil; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Pentosyltransferases; Sodium Compounds; Teniposide; Vincristine | 1991 |
[Gastroenterologic findings in graft versus host disease after allogenic bone marrow transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Infant, Newborn; Intestinal Mucosa; Leukemia, Myeloid, Acute; Liver; Pregnancy; Pregnancy Complications, Neoplastic; Sigmoidoscopy | 1991 |
[Acute myeloblastic leukemia 5q-. Clinical and cytogenetic remission by means of intensive chemotherapy].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Mitoxantrone; Mosaicism; Remission Induction | 1991 |
Granulocytic sarcoma or large cell lymphoma?
Topics: Biopsy; Child, Preschool; Cyclophosphamide; Daunorubicin; Diagnosis, Differential; Etoposide; Female; Humans; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Methotrexate; Thiotepa; Vincristine | 1991 |
Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Etoposide; Humans; Membrane Glycoproteins; Thyroid Neoplasms; Tumor Cells, Cultured; Verapamil; Vincristine | 1990 |
Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cell Survival; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Kinetics; Leukemia, Experimental; Membrane Glycoproteins; Mice; Mutation; Neoplasm Proteins; Phenotype; Verapamil; Vincristine | 1990 |
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Hyperplasia; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Megakaryocytes; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Time Factors | 1991 |
First and second complete remissions in a HIV positive patient following remission induction therapy for acute non-lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; HIV Seropositivity; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Remission Induction; Substance Abuse, Intravenous | 1991 |
[Congenital monoblastic leukemia and self-healing papulonodular cutaneous lesions].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Cytogenetics; Daunorubicin; Etoposide; Female; Humans; Infant, Newborn; Leukemia, Monocytic, Acute; Remission Induction; Skin Diseases | 1990 |
Etoposide in remission induction of adult acute myeloid leukemia.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Thioguanine; Time Factors | 1990 |
Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 1990 |
Drug sensitivity of heat-resistant mouse B16 melanoma variants.
Topics: Acclimatization; Animals; Antineoplastic Agents; Cell Line; Daunorubicin; DNA, Neoplasm; DNA, Single-Stranded; Doxorubicin; Drug Tolerance; Etoposide; Genetic Variation; Hot Temperature; In Vitro Techniques; Melanoma, Experimental; Mice; Tumor Cells, Cultured | 1990 |
Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; France; Humans; Leukemia, Myeloid, Acute; Life Tables; Middle Aged; Neutropenia; Survival Rate | 1990 |
Acute megakaryoblastic leukemia (FAB-M7) in an infant presenting with orbital chloroma and meningeal involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Exophthalmos; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Male; Meningeal Neoplasms; Mitoxantrone; Orbital Neoplasms; Prednisone; Thioguanine; Vincristine | 1990 |
Acute monocytic leukaemia in adults: treatment and prognosis in 99 cases.
Topics: Adolescent; Adult; Aged; Aminacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Male; Middle Aged; Prognosis; Teniposide | 1990 |
Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Line; Colchicine; Daunorubicin; Doxorubicin; Drug Resistance; Enzyme-Linked Immunosorbent Assay; Epirubicin; Etoposide; Glycoproteins; Gramicidin; Humans; Immunosorbent Techniques; Isoxazoles; Lung Neoplasms; Menogaril; Mice; Mice, Inbred BALB C; Mitoxantrone; Nogalamycin; Phenotype; Vinblastine; Vincristine | 1987 |
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Thioguanine | 1987 |
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dactinomycin; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Gene Expression; Humans; Leukemia; Lymphoma; Membrane Glycoproteins; Mitoxantrone; RNA, Messenger; Tumor Cells, Cultured; Vinblastine; Vincristine; Vindesine | 1989 |
[Chemotherapy of adult ANLL].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction; Survival Rate; Vincristine | 1989 |
[Relapse of gingival tumor during hematological remission in acute promyelocytic leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Gingival Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Recurrence; Remission Induction; Vinblastine; Vincristine | 1989 |
Daunomycin, cytosin-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Thioguanine | 1989 |
Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase.
Topics: Amsacrine; Animals; Cell Line; Cricetinae; Cricetulus; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Female; Mutation; Ovary | 1987 |
No response improvement after sequential chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Prednisone; Time Factors; Vincristine | 1986 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Pilot Projects; Thioguanine | 1987 |
Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines.
Topics: Antineoplastic Agents; Daunorubicin; DNA Damage; Drug Resistance; Etoposide; Glutathione; Humans; Tumor Cells, Cultured; Vinblastine; Vincristine | 1988 |
Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Etoposide; Humans; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Leukemia, Lymphoid; Mice; Podophyllotoxin; Verapamil; Vincristine | 1986 |
A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Nausea; Stomatitis; Vomiting | 1986 |
Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Infections; Leukemia, Lymphoid; Male; Neutropenia; Pilot Projects; Thioguanine; Thrombocytopenia | 1987 |
4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male | 1987 |
Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Thioguanine | 1987 |
Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1987 |
Pattern of bone marrow regeneration following chemotherapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Regeneration; Thioguanine | 1987 |
Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia.
Topics: Aclarubicin; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Prognosis | 1986 |
Idarubicin in refractory acute leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Parenteral; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1986 |
Aclacinomycin-A in the induction treatment of childhood AML.
Topics: Aclarubicin; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Naphthacenes; Thioguanine | 1986 |
In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Interactions; Etoposide; In Vitro Techniques; Spectrophotometry | 1987 |
Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1985 |
Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16, 213): implications for mode of action.
Topics: Animals; Daunorubicin; Etoposide; Free Radicals; Lipid Peroxides; Mice; Microsomes, Liver; NADP; Oxygen Consumption; Podophyllotoxin | 1985 |
Free radical metabolism of VP-16 and inhibition of anthracycline-induced lipid peroxidation.
Topics: Animals; Daunorubicin; Etoposide; Free Radicals; Horseradish Peroxidase; Hydrogen Peroxide; Lipid Peroxides; Male; Mice; Microsomes, Liver; Oxygen; Podophyllotoxin | 1983 |
Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line; Cricetinae; Cricetulus; Daunorubicin; Drug Resistance; Etoposide; Female; Mutation; Ovary; Phenotype; Podophyllotoxin; Teniposide | 1983 |
In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).
Topics: Animals; Carcinoma, Ehrlich Tumor; Cisplatin; Daunorubicin; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Kinetics; Mice; Podophyllotoxin; Structure-Activity Relationship | 1982 |
CD7 expression does not predict for poor outcome in acute myeloblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prognosis; Retrospective Studies; Survival Analysis; T-Lymphocyte Subsets | 1995 |
Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.
Topics: Daunorubicin; Drug Resistance, Multiple; Drug Synergism; Etoposide; Humans; Magnetic Resonance Spectroscopy; Propafenone; Structure-Activity Relationship; Tumor Cells, Cultured | 1995 |
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Incompatibility; Drug Stability; Etoposide; Infusions, Intravenous | 1995 |
Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Interleukin-6; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphoma, Non-Hodgkin; Macrophage Colony-Stimulating Factor; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 1993 |
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance.
Topics: ATP-Binding Cassette Transporters; Base Sequence; Biological Transport; Carcinoma, Small Cell; Cell Division; Cell Line; Cell Membrane; Daunorubicin; DNA Primers; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression; Humans; Lung Neoplasms; Membrane Proteins; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Phosphorylation; Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vincristine | 1995 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Molecular Weight | 1994 |
Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates.
Topics: 3T3 Cells; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Carrier Proteins; Colchicine; Daunorubicin; Drug Resistance; Etoposide; Humans; Kinetics; Membrane Glycoproteins; Mice; Quinidine; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity; Vinblastine | 1994 |
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluoresceins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1994 |
A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Thioguanine; Translocation, Genetic | 1994 |
Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Tumor Cells, Cultured | 1993 |
Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells.
Topics: Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carrier Proteins; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Genistein; Humans; Hydrogen-Ion Concentration; Isoflavones; Lung Neoplasms; Membrane Glycoproteins; Neoplasms; Protein-Tyrosine Kinases; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1993 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
Translocation (2;4)(p23;q25): an additional case of a new recurrent anomaly in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 4; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Translocation, Genetic | 1993 |
[Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vinblastine; Vincristine | 1994 |
Acute myeloid leukemia presenting as granulocytic sarcoma of the lung.
Topics: Acute Disease; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Humans; Leukemia, Myeloid; Lung Neoplasms; Male | 1993 |
Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Hemolytic-Uremic Syndrome; Humans; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Plasma Exchange; Platelet Aggregation Inhibitors; Prednisolone; Remission Induction; Zinostatin | 1993 |
Changes in the oral microflora during cytotoxic chemotherapy in children being treated for acute leukemia.
Topics: Adolescent; Analysis of Variance; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Candida albicans; Candidiasis, Oral; Chi-Square Distribution; Child; Child, Preschool; Chlorhexidine; Colony Count, Microbial; Cytarabine; Daunorubicin; Etoposide; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Mouth; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Streptococcus mutans; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1993 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pilot Projects; Prospective Studies; Recurrence; Salvage Therapy; Tumor Stem Cell Assay | 1993 |
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16).
Topics: Cell Survival; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; DNA, Single-Stranded; Drug Interactions; Etoposide; Humans; Razoxane; Tumor Cells, Cultured | 1993 |
Treatment of childhood acute myeloid leukaemia using the BFM-83 protocol.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Life Tables; Male; Survival Analysis; Treatment Outcome | 1993 |
Double mutations of the N-ras gene in a patient with acute myelomonocytic leukemia.
Topics: Aclarubicin; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 9; Codon; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Genes, ras; Genetic Vectors; Humans; Karyotyping; Leukemia, Myelomonocytic, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Point Mutation; Prednisolone; Vinblastine; Vincristine | 1995 |
Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Fungemia; Fungi; Humans; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mycoses; Remission Induction; Retrospective Studies | 1995 |
Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
Topics: Acute Disease; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Catheterization, Central Venous; Cross Infection; Cytarabine; Daunorubicin; Disease Susceptibility; Etoposide; Female; Fever; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Patient Discharge; Safety; Treatment Outcome | 1996 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Finland; Humans; Immunocompromised Host; Incidence; Leukemia; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Pneumonia, Pneumocystis; Prednisone; Premedication; Retrospective Studies; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1996 |
Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mitoxantrone | 1996 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Mercaptopurine; Methotrexate; Methylprednisolone; Neoplasms, Second Primary; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Remission Induction; Scapula; Spinal Neoplasms; Vincristine | 1996 |
A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Cycle Proteins; Chromosome Deletion; Chromosomes, Human, Pair 9; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Deletion; Humans; Immunologic Factors; Interferon-alpha; Male; Neoplasm Proteins; Neoplastic Stem Cells; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Tumor Suppressor Proteins; Vincristine | 1996 |
Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Topoisomerases, Type II; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Leukemia, Myeloid, Acute; Podophyllotoxin; Precipitin Tests; Topoisomerase II Inhibitors | 1996 |
Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blast Crisis; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Hydrogen-Ion Concentration; Idarubicin; Isoenzymes; Leukemia, Myeloid, Acute; Poly-ADP-Ribose Binding Proteins; Prognosis; Tumor Cells, Cultured | 1996 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Marked bone marrow eosinophilia at the time of relapse of acute myeloblastic leukaemia in association with the appearance of translocation t(12;20)(q24;q11).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Eosinophilia; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Translocation, Genetic | 1996 |
A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines.
Topics: Animals; Antineoplastic Agents; Burkitt Lymphoma; Coloring Agents; Daunorubicin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Experimental; Male; Mice; Mice, SCID; Multiple Myeloma; Tetrazolium Salts; Toxicity Tests; Tumor Cells, Cultured | 1996 |
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carrier State; Chronic Disease; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Female; Hepatic Encephalopathy; Hepatitis B; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1996 |
Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Mitoxantrone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Recurrence; Thioguanine | 1995 |
Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
Topics: Bone Marrow; Daunorubicin; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Humans; Idarubicin; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Topoisomerase II Inhibitors | 1997 |
Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells.
Topics: Antioxidants; Camptothecin; Cell Line; Cycloheximide; Dactinomycin; Daunorubicin; DNA; DNA Damage; DNA Topoisomerases, Type I; Etoposide; HIV-1; NF-kappa B; Nucleic Acid Synthesis Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Topoisomerase I Inhibitors; Transcriptional Activation; Virus Activation | 1996 |
Double knockout of the MRP gene leads to increased drug sensitivity in vitro.
Topics: Animals; Antineoplastic Agents; Arsenites; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cell Line; Colchicine; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Targeting; Humans; Mice; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Sodium Compounds; Stem Cells; Teniposide; Vincristine | 1996 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prednisolone; Recombinant Fusion Proteins; RNA, Messenger; Translocation, Genetic | 1997 |
Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; CCAAT-Enhancer-Binding Proteins; Daunorubicin; DNA Fragmentation; DNA-Binding Proteins; Etoposide; HL-60 Cells; Humans; Leukemia; Nuclear Proteins; RNA, Messenger; Serine Proteinase Inhibitors; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured | 1997 |
Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
Topics: Acridines; Affinity Labels; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cyclosporine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fluoresceins; HL-60 Cells; Humans; Isoquinolines; Multidrug Resistance-Associated Proteins; Piperidines; Pyridines; Quinolines; Tetrahydroisoquinolines; Tritium; Verapamil; Vincristine | 1997 |
Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzbromarone; Blotting, Northern; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Ethylmaleimide; Etoposide; Female; Fluoresceins; Humans; Male; Melanoma; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; RNA, Messenger; Tumor Cells, Cultured; Uricosuric Agents; Vinblastine | 1997 |
Antiblastic chemotherapy drugs up-modulate interferon-gamma receptor expression on human malignant T cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Cisplatin; Cytarabine; Daunorubicin; Etoposide; Flow Cytometry; Interferon gamma Receptor; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; Neoplastic Stem Cells; Receptors, Interferon; T-Lymphocytes; Tumor Cells, Cultured; Up-Regulation | 1997 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow; Cell Survival; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Follow-Up Studies; Humans; Infant; Infant, Newborn; Life Tables; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Remission Induction; Tumor Cells, Cultured; Vincristine | 1997 |
Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Colony-Forming Units Assay; Cytarabine; Cytotoxicity, Immunologic; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cells; HL-60 Cells; Humans; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia; Lung Neoplasms; Lymphocyte Activation; Tissue Donors; Transplantation, Autologous; Transplantation, Homologous; Tumor Cells, Cultured | 1997 |
Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents.
Topics: Adenosine Triphosphatases; Amsacrine; Antineoplastic Agents; Aphidicolin; Camptothecin; Dactinomycin; Daunorubicin; DNA; DNA Helicases; Ellipticines; Enzyme Inhibitors; Ethidium; Etoposide; Genistein; Humans; Isoflavones; Nogalamycin; Novobiocin; Topoisomerase I Inhibitors | 1997 |
P-glycoprotein-independent decrease in drug accumulation by phorbol ester treatment of tumor cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Etoposide; Fluoresceins; Humans; Hydrogen-Ion Concentration; KB Cells; Protein Kinase C; Tetradecanoylphorbol Acetate | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Emergence of different mechanisms of resistance in the evolution of multidrug resistance in murine erythroleukemia cell lines.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione; Hydrogen-Ion Concentration; Leukemia, Erythroblastic, Acute; Mice; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1997 |
Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Binding Sites; Biological Transport; Cell Line; Cell Membrane; Colchicine; Cricetinae; Cricetulus; Dactinomycin; Daunorubicin; Doxorubicin; Etoposide; Fluorescence; Fluorescent Dyes; Kinetics; Liposomes; Protein Binding; Quercetin; Rhodamine 123; Rhodamines; Vinblastine | 1997 |
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.
Topics: 4-Chloro-7-nitrobenzofurazan; Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Nucleus; Cholesterol; Cytoplasm; Daunorubicin; Drug Resistance, Multiple; Etoposide; Female; Humans; Norsteroids; Proton-Translocating ATPases; Tumor Cells, Cultured; Vacuolar Proton-Translocating ATPases; Verapamil | 1998 |
MDR1 gene expression and drug resistance of AML cells.
Topics: Aclarubicin; Acute Disease; Antineoplastic Agents; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Genes, MDR; Humans; Lethal Dose 50; Leukemia, Myeloid; Mitoxantrone; Tumor Cells, Cultured | 1998 |
Inhibition of pea chloroplast DNA helicase unwinding and ATPase activities by DNA-interacting ligands.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Amsacrine; Camptothecin; Chloroplasts; Dactinomycin; Daunorubicin; DNA Helicases; Ellipticines; Ethidium; Etoposide; Genistein; Hydrolysis; Intercalating Agents; Ligands; Nogalamycin; Novobiocin; Pisum sativum | 1998 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1998 |
The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
Topics: Adolescent; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Male; Mitoxantrone; Remission Induction | 1998 |
Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blotting, Southern; Cell Survival; Cyclophosphamide; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Humans; Isoenzymes; Leukemia, Myeloid; RNA, Antisense; RNA, Messenger; Tumor Cells, Cultured | 1998 |
Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carboplatin; Cell Line; Cell Survival; Cisplatin; Cricetinae; Cricetulus; Daunorubicin; Doxorubicin; Drug Screening Assays, Antitumor; Electroporation; Etoposide; Lung; Paclitaxel | 1998 |
Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Middle Aged; Neoplasm, Residual; Remission Induction; Tumor Stem Cell Assay | 1998 |
The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Buthionine Sulfoximine; Cell Division; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genes, MDR; Glutathione; Humans; Leukemia; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1998 |
Caspase 7-induced cleavage of kinectin in apoptotic cells.
Topics: Amino Acid Chloromethyl Ketones; Antibodies; Apoptosis; Caspase 7; Caspases; Cell-Free System; Ceramides; Cisplatin; Cysteine Proteinase Inhibitors; Daunorubicin; Etoposide; fas Receptor; HeLa Cells; Humans; Jurkat Cells; Membrane Proteins; Receptors, Cell Surface; Recombinant Proteins | 1998 |
Intensifying induction therapy in acute myeloid leukemia by an infusional chemotherapy schedule.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction | 1998 |
Management of acute promyelocytic leukemia relapse in the ATRA era.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Thioguanine; Treatment Outcome; Tretinoin | 1998 |
A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile.
Topics: Adrenal Cortex Neoplasms; Adult; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Genes, p53; Glucocorticoids; Humans; Male; Mineralocorticoids; Mitotane; Neoplasm Proteins; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Vincristine | 1997 |
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Humans; KB Cells; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multidrug Resistance-Associated Proteins; Phenotype; Prognosis; Treatment Outcome; Tumor Cells, Cultured | 1995 |
P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cohort Studies; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Genes, MDR; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Polysorbates; Surface-Active Agents; Tumor Cells, Cultured | 1999 |
A single apheresis to achieve a high number of peripheral blood CD34+ cells in a lithium-treated patient with acute myeloid leukaemia.
Topics: Adult; Antigens, CD34; Antimanic Agents; Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Blood Cell Count; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Idarubicin; Leukapheresis; Leukemia, Monocytic, Acute; Lithium Carbonate; Mitoxantrone; Recombinant Proteins; Remission Induction; Thioguanine | 1999 |
Long-term molecular remission in promyelocytic transformation of myeloproliferative disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Polycythemia Vera; Preleukemia; Prognosis; Remission Induction; Thrombocythemia, Essential; Thrombophilia; Translocation, Genetic; Tretinoin | 1999 |
Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Caspase 8; Caspase 9; Caspases; Cycloheximide; Cysteine Proteinase Inhibitors; Daunorubicin; Doxorubicin; Enzyme Activation; Etoposide; Fas Ligand Protein; fas Receptor; HeLa Cells; Humans; Jurkat Cells; Membrane Glycoproteins; Mitomycin; Recombinant Fusion Proteins; T-Lymphocytes; Transfection; Tumor Cells, Cultured | 1999 |
A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Chromosome Banding; Cytarabine; Daunorubicin; DNA, Complementary; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Leukemic; Genes, MDR; Humans; K562 Cells; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Oligonucleotide Probes; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Tumor Cells, Cultured | 1999 |
The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Idarubicin; Immunohistochemistry; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Survival Rate; Tretinoin; Vault Ribonucleoprotein Particles | 1999 |
Superoxide anion inhibits drug-induced tumor cell death.
Topics: Apoptosis; Caspase 3; Caspases; Daunorubicin; Drug Interactions; Enzyme Activation; Etoposide; fas Receptor; Humans; Oligodeoxyribonucleotides, Antisense; Pyrimidinones; RNA, Messenger; Superoxide Dismutase; Superoxides; Tumor Cells, Cultured | 1999 |
Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Topics: Aclarubicin; Acute Disease; Antineoplastic Agents; Apoptosis; Cell Nucleus; Comet Assay; Daunorubicin; DNA; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; fas Receptor; Genes, p53; Humans; Intercalating Agents; Leukemia, Myeloid; Mitochondria; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23).
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Amino Acid Sequence; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; DNA, Complementary; Etoposide; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Monocytic, Acute; Molecular Sequence Data; Muscle Proteins; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Nitrosourea Compounds; Nuclear Proteins; Oncogene Proteins, Fusion; Sequence Alignment; Sequence Homology, Nucleic Acid; src Homology Domains | 2000 |
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Breast Neoplasms; Buthionine Sulfoximine; Cell Nucleus; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Flow Cytometry; Glutathione; Glutathione Synthase; Humans; Microscopy, Confocal; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Polymerase Chain Reaction; Spectrometry, Fluorescence; Tumor Cells, Cultured | 2000 |
[Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases].
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Retrospective Studies | 1998 |
Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Camptothecin; Cell Cycle; Cells, Cultured; Daunorubicin; Doxorubicin; Etoposide; Fluorouracil; G1 Phase; Humans; Lymph Nodes; Lymphocyte Depletion; Lymphocytes; Methotrexate; Mice; Mice, Inbred BALB C; Resting Phase, Cell Cycle; Spleen; T-Lymphocytes; Thymus Gland | 2000 |
Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
Topics: Alkynes; Antineoplastic Agents; Camptothecin; Cell Survival; Cisplatin; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione Transferase; Glycine; Humans; Leukemia, Myeloid, Acute; Metallothionein; Paraquat; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Superoxide Dismutase; Tumor Cells, Cultured; Vincristine | 2000 |
Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Ehrlich Tumor; Cell Size; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Immunoassay; Mice; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 2000 |
Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.
Topics: Acridines; Anion Transport Proteins; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Carrier Proteins; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluoresceins; Humans; Isoquinolines; Methamphetamine; Poloxamer; Tetrahydroisoquinolines; Time Factors; Vinblastine | 2000 |
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Topics: Adenovirus E1A Proteins; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Caspase 3; Caspases; CDC2 Protein Kinase; Cell Cycle; Cell Division; Daunorubicin; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases; Microscopy, Phase-Contrast; Nucleic Acid Synthesis Inhibitors; Peptides; Plasmids; Poly(ADP-ribose) Polymerases; Transfection; Tumor Cells, Cultured | 2000 |
Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin.
Topics: Antigens, CD34; Antineoplastic Agents; Cell Survival; Coumarins; Cytarabine; Cytotoxicity Tests, Immunologic; Daunorubicin; DNA, Antisense; Edetic Acid; Etoposide; Flow Cytometry; Granzymes; HeLa Cells; Humans; Isocoumarins; Jurkat Cells; K562 Cells; Leukemia, Myeloid, Acute; Magnesium Chloride; Membrane Glycoproteins; Perforin; Pore Forming Cytotoxic Proteins; Serine Endopeptidases; Tumor Cells, Cultured; U937 Cells | 2000 |
Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fibroblasts; Gene Expression Regulation; Humans; Lung; Lung Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Vinblastine | 2000 |
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Etoposide; Female; Flow Cytometry; Humans; Hydrocortisone; Immunophenotyping; Infant; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Neoplastic Cells, Circulating; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Remission Induction; Treatment Outcome; Vincristine | 2000 |
In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Infant; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Statistics, Nonparametric; Teniposide; Thioguanine; Vincristine | 2000 |
Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Fatal Outcome; Female; Headache; Humans; Immunologic Factors; Injections, Spinal; Interferon alpha-2; Interferon-alpha; Mast-Cell Sarcoma; Nausea; Neoplasm Recurrence, Local; Palliative Care; Papilledema; Parietal Lobe; Prednisolone; Radioisotope Teletherapy; Recombinant Proteins; Remission Induction; Supratentorial Neoplasms; Temporal Lobe; Treatment Failure; Vomiting | 2001 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Neutrophilic eccrine hidradenitis in two neutropaenic patients.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Hidradenitis; Humans; Leukemia, Myeloid; Mitoxantrone | 2001 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Incidence; Leukemia, Myeloid; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Survival Rate; Time Factors; Treatment Failure | 2001 |
Early onset Pneumocystis carinii pneumonia after allogeneic peripheral blood stem cell transplantation.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Immunocompromised Host; Male; Methotrexate; Middle Aged; Opportunistic Infections; Pneumonia, Pneumocystis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Respiratory Insufficiency; Transplantation Conditioning; Transplantation, Autologous; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine; Whole-Body Irradiation | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, Replacement, Hip; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Femur Head Necrosis; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Osteonecrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Treatment Outcome; Vincristine | 2001 |
Erythroleukaemia in the north of England: a population based study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Cytogenetics; Daunorubicin; England; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Prospective Studies; Risk; Survival Rate; Thioguanine; Treatment Outcome; Vidarabine | 2001 |
Efficiency of homocysteine plus copper in inducing apoptosis is inversely proportional to gamma-glutamyl transpeptidase activity.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Membrane Permeability; Cell Nucleus; Cells, Cultured; Copper; Cytarabine; Daunorubicin; Endothelium, Vascular; Etoposide; gamma-Glutamyltransferase; Homocysteine; Humans; Time Factors; Vinblastine | 2001 |
Role of palmitoyl-protein thioesterase in cell death: implications for infantile neuronal ceroid lipofuscinosis.
Topics: Antibiotics, Antineoplastic; Apoptosis; Chromones; Daunorubicin; Enzyme Inhibitors; Etoposide; Humans; Infant; Morpholines; Nerve Degeneration; Neuroblastoma; Neuronal Ceroid-Lipofuscinoses; Neurons; Nucleic Acid Synthesis Inhibitors; Sphingosine; Staurosporine; Thiolester Hydrolases; Transfection; Tumor Cells, Cultured | 2001 |
Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Carcinoma, Ehrlich Tumor; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione; Mice; Neoplasm Proteins; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Stem Cell Assay; Verapamil; Vincristine | 2001 |
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clone Cells; Colchicine; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Lung Neoplasms; Models, Biological; Proline; Promoter Regions, Genetic; Protein Structure, Tertiary; Recombinant Fusion Proteins; Structure-Activity Relationship; Tetracycline; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Caspases; Child; Child, Preschool; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Daunorubicin; Dexamethasone; Enzyme Induction; Etoposide; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genes, bcl-2; Genes, p53; Humans; Idarubicin; Infant; Male; Neoplasm Proteins; Neoplastic Stem Cells; Nuclear Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Thioguanine; Tumor Suppressor Protein p53; Vincristine | 2002 |
C-Jun modulates apoptosis but not terminal cell differentiation in murine erythroleukemia cells.
Topics: Animals; Anisomycin; Antibiotics, Antineoplastic; Apoptosis; Cell Differentiation; Culture Media, Serum-Free; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Daunorubicin; Dimethyl Sulfoxide; DNA, Antisense; Enzyme Activation; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Leukemic; Genes, jun; JNK Mitogen-Activated Protein Kinases; Leukemia, Erythroblastic, Acute; Mice; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-jun; Recombinant Fusion Proteins; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
Chemotherapy and pregnancy.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Fetus; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Topotecan; Trastuzumab; Vinblastine; Vincristine | 2002 |
Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cerebral Infarction; Child; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Humans; Hypertension; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Obesity; Remission Induction; Thioguanine | 2001 |
Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Encephalitis, Viral; Etoposide; Fatal Outcome; Female; Fetal Blood; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transplantation; Herpesvirus 6, Human; Humans; Immunocompromised Host; Korsakoff Syndrome; Leukemia, Myeloid, Acute; Recurrence; Roseolovirus Infections; Transplantation Conditioning; Transplantation, Homologous; Virus Activation | 2001 |
Gynecomastia with marked cellular atypia associated with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms, Male; Carcinoma, Intraductal, Noninfiltrating; Cytarabine; Daunorubicin; Diagnostic Errors; Etoposide; Gynecomastia; Humans; Leukemia, Myelomonocytic, Acute; Male | 2002 |
Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition.
Topics: Antineoplastic Agents, Phytogenic; Catalysis; Cell Survival; Cells, Cultured; Daunorubicin; DNA Damage; Drug Interactions; Ethylmaleimide; Etoposide; Humans; Maleimides; Topoisomerase II Inhibitors | 2002 |
Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Immunophenotyping; Male; Mercaptopurine; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Risk Factors; Treatment Outcome; Vincristine | 2002 |
Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Cell Division; Cell Survival; Cell-Free System; Cisplatin; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Mitoxantrone; Molecular Sequence Data; Neoplasm Proteins; Peptides; Phenotype; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; RNA, Catalytic; RNA, Messenger; Stomach Neoplasms; Time Factors; Transfection; Tumor Cells, Cultured | 2002 |
A case of acantholytic dermatosis and leukemia cutis: cause or effect?
Topics: Acantholysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Skin; Skin Neoplasms; Treatment Outcome | 2002 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Anti-angiogenic activity of the purine analog 6-thioguanine.
Topics: 2-Aminopurine; Acute Disease; Aged; Allantois; Anemia; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cattle; Cell Line, Transformed; Chick Embryo; Chorion; Cytarabine; Daunorubicin; Drug Evaluation; Endothelial Growth Factors; Endothelium, Vascular; Etoposide; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Humans; Leukemia, Myeloid; Lymphokines; Male; Mice; Mice, Inbred BALB C; Middle Aged; Neovascularization, Pathologic; Neovascularization, Physiologic; Remission Induction; Stress, Mechanical; Thioguanine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Diseases, Metabolic; Child; Daunorubicin; Etoposide; Female; Glucocorticoids; Hematologic Neoplasms; Humans; Osteoblasts; Stem Cells; Tumor Cells, Cultured; Vincristine | 2002 |
Blast crisis of chronic myeloid leukemia: diagnosis prompted by T(8;9).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Child, Preschool; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Ethmoid Sinus; Etoposide; Fusion Proteins, bcr-abl; Humans; Karyotyping; Leukemia, Myeloid, Accelerated Phase; Male; Meninges; Mitoxantrone; Remission Induction; Sacrococcygeal Region; Sarcoma, Myeloid; Thioguanine; Translocation, Genetic | 2002 |
Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure.
Topics: Acute Kidney Injury; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Child; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Hemofiltration; Humans; Leukapheresis; Leukemia, Monocytic, Acute; Male; Metabolic Clearance Rate; Recombinant Proteins; Remission Induction; Renal Dialysis; Urate Oxidase | 2002 |
Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxycholic Acid; Drug Combinations; Drug Resistance, Fungal; Etoposide; Fatal Outcome; Humans; Immunocompromised Host; Itraconazole; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelomonocytic, Acute; Liposomes; Lung Diseases, Fungal; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Triazoles; Voriconazole | 2002 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Death; Cell Differentiation; Daunorubicin; Etoposide; Gene Expression Regulation, Neoplastic; Genetic Therapy; HL-60 Cells; Humans; Leukemia, Myeloid; Oligodeoxyribonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; RNA Interference; RNA, Double-Stranded; Signal Transduction; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 2003 |
Long-term outcomes of acute myeloid leukemia in adults in Pakistan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pakistan; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Kuwait; Leucovorin; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Mercaptopurine; Mesna; Methotrexate; Neoplasm Staging; Prednisolone; Prednisone; Survival Rate; Thioguanine; Treatment Outcome; Vincristine | 2003 |
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured | 2003 |
[Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; K562 Cells; Oxides | 2003 |
[Campaign of eradication of Ades aegypti in Chili].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Culicidae; Cytarabine; Daunorubicin; Etoposide | 1953 |
Acute myeloid leukemia presenting as non-neutropenic colitis in an infant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis; Colon; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; Infant; Leukemia, Myeloid, Acute; Leukemic Infiltration; Leukocyte Common Antigens; Peroxidase; Sigmoidoscopy; Thioguanine | 2003 |
Isolated IgA deficiency after chemotherapy for acute myelogenous leukemia in an infant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Humans; IgA Deficiency; Immunoglobulins, Intravenous; Infant; Leukemia, Monocytic, Acute; Male; Thioguanine | 2003 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2003 |
Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Daunorubicin; Etoposide; Female; Humans; Liposomes; Magnetic Resonance Imaging; Male; Survival Analysis; Treatment Outcome | 2004 |
Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cytarabine; Daunorubicin; Etoposide; Female; Hemoglobins; Hemorrhage; Humans; Jehovah's Witnesses; Leukemia; Male; Middle Aged; Multiple Organ Failure; Patient Acceptance of Health Care; Refusal to Treat; Remission Induction; Tretinoin; Vincristine | 2004 |
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Treatment Outcome | 2004 |
A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Treatment Outcome | 2004 |
Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Malaysia; Male; Treatment Outcome | 2004 |
Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Survival Analysis | 2005 |
Immune thrombocytopenia following successful treatment of cancer in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Carmustine; Child, Preschool; Cyclophosphamide; Daunorubicin; Etoposide; Female; Humans; Infant; Male; Neoplasms; Platelet Count; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Vincristine | 2006 |
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Topics: Anemia; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Cell Culture Techniques; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Etoposide; Female; Leukopenia; Mice; Neutropenia; Razoxane; Thrombocytopenia | 2005 |
Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Tretinoin | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Statistics, Nonparametric; Survival Analysis | 2005 |
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Topics: Acute Disease; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Oligospermia; Sperm Motility; Spermatozoa | 2005 |
Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Bone Marrow Cells; Cell Cycle; Cells, Cultured; Daunorubicin; DNA Damage; Etoposide; GADD45 Proteins; Hematopoietic Stem Cells; Intracellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Oxidative Stress; Retroviridae; Ultraviolet Rays; Ultraviolet Therapy | 2005 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Proliferation; Cytarabine; Daunorubicin; DNA; Etoposide; Flow Cytometry; Fluorescent Dyes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrocarbons, Chlorinated; Leukemia; Leukemia, Myeloid, Acute; Microscopy, Fluorescence; Oligopeptides; Organic Chemicals; Radiation-Protective Agents | 2005 |
T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cell Differentiation; Cell Lineage; Core Binding Factor Alpha 2 Subunit; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Diagnosis, Differential; Doxorubicin; Etoposide; Fatal Outcome; Female; Gene Dosage; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Karyotyping; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Neoplastic Stem Cells; Proto-Oncogenes; Recurrence; T-Lymphocyte Subsets; Vincristine | 2007 |
Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Clone Cells; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Cytarabine; Daunorubicin; Dexamethasone; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Glucocorticoids; Graft vs Host Disease; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Leukemia-Lymphoma, Adult T-Cell; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Postoperative Complications; Prednisolone; Rituximab; Time Factors; Transplantation Chimera; Transplantation Conditioning; Vincristine; Virus Activation; Whole-Body Irradiation | 2005 |
Chemosensitivity of drug-sensitive and drug-resistant P388 leukemia cell lines after hyperthermic treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hyperthermia, Induced; Leukemia P388; Mice | 1989 |
Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Male; Mercaptopurine; Methotrexate; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Survival Analysis; Thioguanine; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vincristine | 2007 |
Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclosporins; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Verapamil | 2006 |
Shifting to outpatient management of acute myeloid leukemia: a prospective experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Feasibility Studies; Female; Humans; Inpatients; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Outpatients; Patient Discharge; Patient Readmission; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome | 2006 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Structure-Activity Relationship; Thiazolidinediones; Troglitazone; U937 Cells | 2006 |
Heterologous expression of a mammalian ABC transporter in plant and its application to phytoremediation.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Biodegradation, Environmental; Cadmium; Daunorubicin; Etoposide; Humans; Intracellular Membranes; Multidrug Resistance-Associated Proteins; Nicotiana; Plants, Genetically Modified; Vacuoles | 2006 |
Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Infant; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Neoplasm Proteins; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Translocation, Genetic; WT1 Proteins | 2007 |
Zygomycosis in the immunocompromised patient: a case report.
Topics: Absidia; Acute Disease; Aerosols; Amphotericin B; Amsacrine; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Debridement; Drug Resistance, Fungal; Drug Resistance, Neoplasm; Etoposide; Fluconazole; Humans; Immunocompromised Host; Leukemia; Liposomes; Middle Aged; Mucormycosis; Sinusitis; Tomography, X-Ray Computed | 2006 |
Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Brain Abscess; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Daunorubicin; Dexamethasone; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Liposomes; Lung Diseases, Fungal; Mercaptopurine; Mitoxantrone; Mucormycosis; Pneumonia, Viral; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Transplantation, Homologous; Vincristine | 2006 |
[Twenty years of treating childhood acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Male; Mercaptopurine; Methotrexate; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Prognosis; Recurrence; Risk Factors; Survival Rate; Time Factors; Vincristine | 2006 |
Acute myelogenous leukemia associated with Ollier disease.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 21; Cytarabine; Daunorubicin; Enchondromatosis; Etoposide; Gemtuzumab; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplastic Syndromes, Hereditary; Translocation, Genetic | 2008 |
Amrubicin induces apoptosis in human tumor cells mediated by the activation of caspase-3/7 preceding a loss of mitochondrial membrane potential.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 7; Cell Division; Daunorubicin; Drug Therapy, Combination; Enzyme Activation; Etoposide; G2 Phase; Humans; Membrane Potentials; Mitochondria; Tumor Cells, Cultured; U937 Cells | 2006 |
Increased mortality with FLA compared with ADE chemotherapy in high-risk AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2006 |
IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells.
Topics: Animals; Apoptosis; Benzamides; Caspases; Cell Line; Cyclohexanones; Daunorubicin; Enzyme Activation; Etoposide; Hodgkin Disease; Humans; I-kappa B Kinase; I-kappa B Proteins; Leukocytes, Mononuclear; Mice; Mutation; Neoplasm Transplantation; NF-kappa B; NF-KappaB Inhibitor alpha; Reed-Sternberg Cells; Topoisomerase Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2007 |
Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Topics: Animals; Cell Survival; Cells, Cultured; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Etoposide; In Vitro Techniques; Injections; Male; Maximum Tolerated Dose; Pigment Epithelium of Eye; Rabbits; Topoisomerase II Inhibitors; Vitreoretinopathy, Proliferative; Vitreous Body | 2007 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antigens, Neoplasm; Blood Cells; Bone Marrow Cells; Cell Survival; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; RNA, Messenger | 2007 |
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Evidence-Based Medicine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vincristine | 2007 |
Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Bone Marrow; Cell Nucleus; Cytarabine; Cytoplasm; Daunorubicin; Electrophoretic Mobility Shift Assay; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Leukemic; Humans; Immunoprecipitation; Leukemia, Myeloid, Acute; Mutation; NF-kappa B; Nuclear Proteins; Nucleophosmin; Tumor Cells, Cultured | 2008 |
[Effectiveness of the AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Tretinoin | 2008 |
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Busulfan; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Prognosis; Proportional Hazards Models; Statistics, Nonparametric | 2008 |
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepidermoid; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Image Processing, Computer-Assisted; Leukemia, Myeloid, Acute; Male; Neck Dissection; Neoplasms, Second Primary; Positron-Emission Tomography; Submandibular Gland Neoplasms; Thioguanine; Tomography, X-Ray Computed; Transplantation Conditioning | 2009 |
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; B-Lymphocytes; Camptothecin; Carboplatin; Cell Proliferation; Cell Survival; Cells, Cultured; Cisplatin; Daunorubicin; Enzyme Inhibitors; Etoposide; Exodeoxyribonucleases; Genotype; Humans; Platinum Compounds; Polymorphism, Single Nucleotide; RecQ Helicases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase Inhibitors; Werner Syndrome; Werner Syndrome Helicase | 2009 |
[Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Cyclophosphamide; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Middle Aged; Prednisone; Procarbazine; Remission Induction; Treatment Outcome; Vincristine | 2008 |
Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Charcot-Marie-Tooth Disease; Contraindications; Cytarabine; Daunorubicin; Etoposide; Gait Disorders, Neurologic; Humans; Male; Mercaptopurine; Methotrexate; Muscle Weakness; Neural Conduction; Peripheral Nervous System Diseases; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Vincristine | 2008 |
Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Injections, Spinal; Male; Mercaptopurine; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; T-Lymphocytes; Treatment Outcome; Vincristine | 2009 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Acute myelogenous leukemia presenting as acute infectious meningitis in a 7-year-old boy.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Ceftriaxone; Child; Chromosomes, Human, Pair 10; Cytarabine; Daunorubicin; Diagnosis, Differential; Escherichia coli Infections; Etoposide; Flow Cytometry; Gemtuzumab; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Meningitis, Bacterial; Patient Transfer; Spinal Puncture; Trisomy | 2009 |
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Salvage Therapy; Vincristine; Vindesine; Young Adult | 2009 |
siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Cell Division; Cell Line, Tumor; Daunorubicin; DNA Primers; Down-Regulation; Etoposide; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Repressor Proteins; RNA, Messenger; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2009 |
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; K562 Cells; Leukemia; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Stomach Neoplasms; Vincristine | 2009 |
Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Cytarabine; Cytotoxins; Daunorubicin; Drug Evaluation, Preclinical; Drug Synergism; Etoposide; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Models, Biological; Nitrophenols; Peptide Initiation Factors; Piperazines; Protein Biosynthesis; Protein Synthesis Inhibitors; Sulfonamides; Triterpenes; U937 Cells | 2010 |
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cellular Senescence; Cytarabine; Daunorubicin; Etoposide; Genes, ras; Humans; Leukemia, Myeloid, Acute; Mutation; ras Proteins; Tumor Suppressor Protein p53 | 2009 |
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Gemtuzumab; HL-60 Cells; Humans; Idarubicin; Immunotoxins; Leukemia; Mercaptopurine; Methotrexate; Mitoxantrone; Sialic Acid Binding Ig-like Lectin 3; U937 Cells; Vincristine | 2009 |
Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Etoposide; Humans; Intestinal Neoplasms; Lymphoma, T-Cell; Male; Mercaptopurine; Methotrexate; Methylprednisolone; Neoplasm Staging; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Thioguanine; Vincristine | 2010 |
Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Injections, Spinal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Male; Meninges; Middle Aged; Mitoxantrone; Testis; Young Adult | 2010 |
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Survival; Daunorubicin; Etoposide; Factor Xa; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Glycoproteins; Microscopy, Confocal; Milk Proteins; Oxides; Phosphatidylserines; Thrombin; Thromboplastin; Tretinoin; Young Adult | 2010 |
Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclin D3; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Male; Mercaptopurine; Methotrexate; Middle Aged; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Proportional Hazards Models; Remission Induction; Survival Rate; Transcription Factors; Vincristine; Young Adult | 2010 |
Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma.
Topics: Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Etoposide; Humans | 2010 |
MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Etoposide; Humans; Male; MicroRNAs; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sirtuin 1; Tumor Suppressor Protein p53 | 2010 |
Adhesion-induced drug resistance in leukemia stem cells.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Coculture Techniques; Cyclin-Dependent Kinase Inhibitor Proteins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia; Lysosomes; Neoplastic Stem Cells; Osmolar Concentration; Proto-Oncogene Proteins c-bcl-2; Stem Cell Niche; Stromal Cells; Up-Regulation; Vacuolar Proton-Translocating ATPases | 2010 |
Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Gene Expression Profiling; Humans; I-kappa B Proteins; Leukemia, Myeloid, Acute; Lymphocytes; Oligonucleotide Array Sequence Analysis; Pyrimidines | 2011 |
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cytarabine; Cytosine; Daunorubicin; Etoposide; Female; Flavonoids; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Vidarabine; Young Adult | 2011 |
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin.
Topics: Adenosine Triphosphatases; Camptothecin; Cisplatin; Dactinomycin; Daunorubicin; DNA Helicases; Ellipticines; Enzyme Inhibitors; Etoposide; Intercalating Agents; Mitoxantrone; Nogalamycin; Novobiocin; Pisum sativum; Plant Proteins | 2011 |
Siblings presenting with progressive congenital aleukemic leukemia cutis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Siblings; Skin Neoplasms; Thioguanine | 2011 |
Copy number polymorphisms and anticancer pharmacogenomics.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carboplatin; Cell Line, Tumor; Cisplatin; Daunorubicin; Etoposide; Gene Dosage; Gene Expression; Genetic Predisposition to Disease; Genetic Variation; Genome-Wide Association Study; Genome, Human; Humans; Inhibitory Concentration 50; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Topoisomerase II Inhibitors | 2011 |
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busulfan; Cell Line, Tumor; Daunorubicin; Drug Interactions; Drug Synergism; Etoposide; Exotoxins; Flow Cytometry; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia; Leukocytes; Lymphocyte Function-Associated Antigen-1; Membrane Potential, Mitochondrial; Mitoxantrone; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2011 |
Myeloid sarcoma in a child with acute myeloblastic leukaemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Cytosine; Daunorubicin; Etoposide; Exophthalmos; Humans; Leukemia, Myeloid, Acute; Male; Paranasal Sinus Neoplasms; Parotid Gland; Sarcoma, Myeloid | 2011 |
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Pilot Projects; Prognosis; Survival Rate; Young Adult | 2012 |
Unexpected pancytopenia following treatment of acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Erythropoiesis; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Pancytopenia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Translocation, Genetic; Vincristine | 2012 |
Circadian clock protein BMAL1 regulates cellular senescence in vivo.
Topics: Animals; Antineoplastic Agents; ARNTL Transcription Factors; Cell Death; Cellular Senescence; Circadian Clocks; Culture Media, Serum-Free; Daunorubicin; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Fibroblasts; Gene Expression Regulation, Neoplastic; Homeostasis; Hydrogen Peroxide; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Primary Cell Culture; Reactive Oxygen Species; Time Factors | 2011 |
A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Down Syndrome; Down-Regulation; Etoposide; GATA1 Transcription Factor; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Interleukin-1alpha; Lentivirus; Leukemia, Megakaryoblastic, Acute; Megakaryocytes; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering | 2011 |
Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Feasibility Studies; Female; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Outpatients; Patient Readmission | 2012 |
Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Posterior Leukoencephalopathy Syndrome; Young Adult | 2012 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |
Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CD24 Antigen; Cell Division; Cell Line, Tumor; Daunorubicin; Dipeptidyl Peptidase 4; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Gene Expression; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Mesothelioma; Neoplasm Invasiveness; Neoplastic Stem Cells; RNA Interference; RNA, Small Interfering | 2012 |
Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Chromosome Aberrations; Cohort Studies; Comorbidity; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunophenotyping; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Palliative Care; Remission Induction; Retrospective Studies; Serbia; Treatment Outcome | 2012 |
Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cytarabine; Daunorubicin; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Hepatomegaly; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Middle Aged; Multivariate Analysis; Muscle Proteins; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-bcl-2; Splenomegaly; Treatment Outcome; Up-Regulation; Young Adult | 2012 |
Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Male; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Vincristine | 2012 |
Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cohort Studies; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Health Resources; Hospitals, Pediatric; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Logistic Models; Male; Odds Ratio; Poisson Distribution; Risk Assessment; Risk Factors; Thioguanine; Treatment Outcome; United States | 2013 |
EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Daunorubicin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; MDS1 and EVI1 Complex Locus Protein; Mice; Myeloid Cells; Proto-Oncogenes; Transcription Factors; Up-Regulation | 2013 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Topics: Aged; Aged, 80 and over; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk; Severity of Illness Index; Treatment Outcome | 2013 |
Plasmodium falciparum UvrD activities are downregulated by DNA-interacting compounds and its dsRNA inhibits malaria parasite growth.
Topics: Antigens, Protozoan; Cells, Cultured; Daunorubicin; DNA Helicases; DNA, Protozoan; Ethidium; Etoposide; Humans; Malaria, Falciparum; Molecular Targeted Therapy; Netropsin; Nogalamycin; Plasmodium falciparum; RNA, Double-Stranded; RNA, Protozoan | 2014 |
The ROS/SUMO axis contributes to the response of acute myeloid leukemia cells to chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cytarabine; Daunorubicin; Disease Models, Animal; Etoposide; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Microarray Analysis; Reactive Oxygen Species; SUMO-1 Protein; U937 Cells; Xenograft Model Antitumor Assays | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Osteopontin upregulates the expression of glucose transporters in osteosarcoma cells.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Daunorubicin; Etoposide; Fluorouracil; Glucose Transport Proteins, Facilitative; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Integrin alphaVbeta3; Membrane Transport Modulators; Methotrexate; Osteopontin; Osteosarcoma; Phloretin; Up-Regulation | 2014 |
Eccrine poromatosis in a patient with acute myeloid leukemia following chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Poroma; Stem Cell Transplantation; Sweat Gland Neoplasms | 2014 |
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child Health Services; Child, Preschool; Comparative Effectiveness Research; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Health Information Systems; Hospitals, Pediatric; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Outcome and Process Assessment, Health Care; Young Adult | 2015 |
Chemical profiling of the genome with anti-cancer drugs defines target specificities.
Topics: Aclarubicin; Antineoplastic Agents; Cell Line, Tumor; Chromatin; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genome, Human; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Organ Specificity; Protein Transport; Structure-Activity Relationship; Topoisomerase Inhibitors; Topotecan | 2015 |
ATPase activity of Plasmodium falciparum MLH is inhibited by DNA-interacting ligands and dsRNAs of MLH along with UvrD curtail malaria parasite growth.
Topics: Adenosine Triphosphatases; Antimalarials; Daunorubicin; DNA Helicases; DNA Mismatch Repair; DNA, Protozoan; Drug Resistance; Ethidium; Etoposide; Malaria, Falciparum; Molecular Docking Simulation; MutL Protein Homolog 1; Netropsin; Nogalamycin; Plasmodium falciparum; RNA, Double-Stranded | 2017 |
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cytarabine; Dacarbazine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Iodobenzenes; Leukemia, Myeloid, Acute; Male; Paraganglioma; Radiation Tolerance; Temozolomide | 2017 |
Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Thioguanine; Tumor Suppressor Protein p53 | 2017 |
Unexpected diagnosis of appendicitis in a paediatric patient with febrile neutropaenia and acute myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Febrile Neutropenia; Humans; Incidental Findings; Leukemia, Myeloid, Acute; Male; Tomography, X-Ray Computed | 2017 |
Acute myeloid leukaemia masquerading as a primary CNS tumour.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; fms-Like Tyrosine Kinase 3; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Sarcoma, Myeloid; Treatment Outcome | 2017 |
Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Delayed Diagnosis; Etoposide; Fatal Outcome; Fatigue; Female; Fever; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Leukocytosis; Metrorrhagia; Middle Aged; Myoma; Neoplasms, Multiple Primary; Palliative Care; Skin; Uterine Neoplasms | 2017 |
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Topics: Aminopyridines; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Daunorubicin; DNA Damage; DNA Glycosylases; DNA Repair; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Lung Neoplasms; Piperazines; Poly (ADP-Ribose) Polymerase-1; Promoter Regions, Genetic; Purines; Pyridines | 2018 |
Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2018 |
Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chromosome Inversion; Chromosomes, Human, Pair 16; Core Binding Factor beta Subunit; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocytosis; Longitudinal Studies; Male; Middle Aged; Morocco; Myosin Heavy Chains; Oncogene Proteins, Fusion; Prognosis; Young Adult | 2018 |
Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Daunorubicin; Doxorubicin; Drug Monitoring; Etoposide; Fluorescence; Humans; Limit of Detection; Male; Neoplasms; Occupational Exposure; Personnel, Hospital; Prednisone; Reproducibility of Results; Solid Phase Extraction; Vincristine | 2018 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.
Topics: Bone Marrow; Bone Marrow Cells; Cell Line; Cell Line, Tumor; Cytarabine; Cytochrome P-450 CYP3A; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Stromal Cells; Tumor Microenvironment; Up-Regulation | 2019 |
Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.
Topics: Abnormal Karyotype; Adolescent; Allografts; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression Regulation, Leukemic; Genes, Mitochondrial; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mitochondrial Proteins; Neoplasm Proteins; Prognosis; Progression-Free Survival; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2019 |
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine | 2020 |
A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome.
Topics: Antineoplastic Agents; Autistic Disorder; Child; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Intellectual Disability; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 3; Myeloid-Lymphoid Leukemia Protein; Vault Ribonucleoprotein Particles | 2021 |
Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
Topics: Adolescent; Adult; Age of Onset; Aged; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Child; Child, Preschool; Cohort Studies; Cytarabine; Daunorubicin; Egypt; Etoposide; Female; Humans; Incidence; Induction Chemotherapy; Infant; Leukemia, Biphenotypic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Treatment Outcome; Young Adult | 2021 |
COVID-19 reinfection in two children with cancer.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carboplatin; Child, Preschool; Cisplatin; COVID-19; Cyclophosphamide; Daunorubicin; Etoposide; Humans; Male; Neuroblastoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Reinfection; SARS-CoV-2; Vincristine | 2021 |
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gemtuzumab; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Polymorphism, Single Nucleotide; Prognosis; Survival Rate; Young Adult | 2022 |
Different effects of magnetic field on drug activity in human uterine sarcoma cell lines MES-SA and MES-SA/Dx5.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Humans; Magnetic Fields; Sarcoma; Uterine Neoplasms | 2022 |
Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: A single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Humans; Mercaptopurine; Methotrexate; Outpatients; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |